{
    "PMC": "11662158",
    "DOI": "10.1002/bies.202400023",
    "PMID": "39367555",
    "PMCID": "PMC11662158",
    "title": "Mitochondrial dysfunction, cause or consequence in neurodegenerative diseases?",
    "year": 2025,
    "source_url": "https://europepmc.org/article/PMC/PMC11662158",
    "source": "MED",
    "abstract_text": "Neurodegenerative diseases encompass a spectrum of conditions characterized by the gradual deterioration of neurons in the central and peripheral nervous system. While their origins are multifaceted, emerging data underscore the pivotal role of impaired mitochondrial functions and endolysosomal homeostasis to the onset and progression of pathology. This article explores whether mitochondrial dysfunctions act as causal factors or are intricately linked to the decline in endolysosomal function. As research delves deeper into the genetics of neurodegenerative diseases, an increasing number of risk loci and genes associated with the regulation of endolysosomal and autophagy functions are being identified, arguing for a downstream impact on mitochondrial health. Our hypothesis centers on the notion that disturbances in endolysosomal processes may propagate to other organelles, including mitochondria, through disrupted inter-organellar communication. We discuss these views in the context of major neurodegenerative diseases including Alzheimer's and Parkinson's diseases, and their relevance to potential therapeutic avenues.",
    "full_text": "pmc Bioessays Bioessays 10.1002/(ISSN)1521-1878 BIES Bioessays 0265-9247 1521-1878 John Wiley and Sons Inc. Hoboken 11662158 39367555 10.1002/bies.202400023 BIES202400023 Review REVIEW Prospects & Overviews Mitochondrial dysfunction, cause or consequence in neurodegenerative diseases? VAN ACKER et al . Van Acker Zo\u00eb P. 1 2 Leroy Thomas 1 2 Annaert Wim https://orcid.org/0000-0003-0150-9661 1 2 wim.annaert@kuleuven.be 1 Laboratory for Membrane Trafficking VIB Center for Brain & Disease Research Leuven Belgium 2 Department of Neurosciences KU Leuven Leuven Belgium * Correspondence Wim Annaert, Laboratory for Membrane Trafficking, VIB\u2010Center for Brain and Disease Research, Department of Neurosciences, KU Leuven, B\u20103000 Leuven, Belgium. Email: wim.annaert@kuleuven.be 04 10 2024 1 2025 47 1 10.1002/bies.v47.1 2400023 29 7 2024 26 1 2024 20 9 2024 \u00a9 2024 The Author(s). BioEssays published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non\u2010commercial and no modifications or adaptations are made. Abstract Neurodegenerative diseases encompass a spectrum of conditions characterized by the gradual deterioration of neurons in the central and peripheral nervous system. While their origins are multifaceted, emerging data underscore the pivotal role of impaired mitochondrial functions and endolysosomal homeostasis to the onset and progression of pathology. This article explores whether mitochondrial dysfunctions act as causal factors or are intricately linked to the decline in endolysosomal function. As research delves deeper into the genetics of neurodegenerative diseases, an increasing number of risk loci and genes associated with the regulation of endolysosomal and autophagy functions are being identified, arguing for a downstream impact on mitochondrial health. Our hypothesis centers on the notion that disturbances in endolysosomal processes may propagate to other organelles, including mitochondria, through disrupted inter\u2010organellar communication. We discuss these views in the context of major neurodegenerative diseases including Alzheimer's and Parkinson's diseases, and their relevance to potential therapeutic avenues. Endolysosomal and mitochondrial dysfunctions are major pathological hallmarks in neurodegeneration. In healthy neurons, lysosomes maintain mitochondrial health through membrane contact sites and local translation. In disease, failing lysosomal degradation compromises mitophagy, activating cGAS\u2010STING leading to further congestion and immune responses. Many risk genes in neurodegeneration indeed function in lysosomal/autophagy regulation. lysosomal homeostasis mitochondrial homeostasis neurodegenerative diseases Alzheimer's Association 10.13039/100000957 AARF\u201020\u2010677499 Fonds Wetenschappelijk Onderzoek 10.13039/501100003130 11K1122N 1250425N G0C3620N G0C4220N I001322N Stichting Alzheimer Onderzoek #2020/030 2022/022 2023/034 Vlaams Instituut voor Biotechnologie 10.13039/501100004727 KU Leuven 10.13039/501100004040 C14/21/095 SMINF KA/20/085 source-schema-version-number 2.0 cover-date January 2025 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.1 mode:remove_FC converted:21.12.2024 Van Acker , Z. P. , Leroy , T. , & Annaert , W. ( 2025 ). Mitochondrial dysfunction, cause or consequence in neurodegenerative diseases? BioEssays , 47 , e2400023 . 10.1002/bies.202400023 1 INTRODUCTION Mitochondria are essential in generating ATP, the primary energy source for cellular metabolism, through a process called oxidative phosphorylation (OXPHOS). In this process, redox reactions create a proton gradient across the electron transport chain (ETC), which is then used by ATP synthase to produce ATP. This energy is necessary for several cellular functions including protein synthesis, (vesicular) transport, maintenance of membrane potential and synaptic plasticity. In addition, mitochondria play a role in the production of critical metabolites including haem as well as the regulation of cell death and calcium homeostasis. [ 1 ] Because of their vital role in health maintenance, mitochondrial dysfunctions can be the root cause of a variety of disorders. Primary mitochondrial illnesses are a group of genetic disorders characterized by abnormalities in mitochondrial and/or nuclear DNA encoding directly or indirectly essential genes of the OXPHOS process. [ 2 ] Mutations in these genes can cause heart failure, visual impairments or muscular weakness. In contrast, secondary mitochondrial diseases are characterized by genetic abnormalities in mitochondrial and/or nuclear DNA encoding non\u2010OXPHOS related genes. This group includes neurodegenerative disorders, cancer, and obesity, all of which involve some degree of mitochondrial malfunction. [ 3 ] While mitochondria have been extensively linked and studied in the context of neurodegeneration, genetics is increasingly pivoting to endolysosomal dyshomeostasis as a major player in disease onset and progression. [ 4 , 5 , 6 ] Clearly, the unique morphology of differentiated neurons requires robust organellar homeostatic mechanisms. These highly differentiated cells comprise of a soma, a lengthy axon, and thick dendrites with numerous branches. The distinctive metabolic demands of these components lead to an uneven distribution of mitochondria. [ 7 ] Axonal mitochondria are notably more active than their dendritic counterparts [ 8 ] ; meaning they also need to be replaced in time. While neurons might last a lifetime, the proteins and organelles that build them up have to be recycled on a regular basis. Mitochondrial DNA has been shown to have a half\u2010life of approximately 31 days in brain tissue [ 9 ] . More often than in the axon, mitochondria are mostly recycled in the soma within degradative lysosomes. [ 10 , 11 , 12 ] Basal turnover of mitochondrial nucleoids and the selective destruction of harmed or malfunctioning mitochondria is a process known as mitophagy. [ 10 , 11 ] The importance of the process has been nicely demonstrated using mass spectrometry analysis of isolated autophagic vesicles from the brains of healthy adult mice, showing that mitochondrial proteins make up nearly half of the unique autophagy cargo. [ 10 , 11 ] In neurons, lysosomes are composed of a heterogeneous and dynamic population in which different functions are fulfilled depending on the requirements of the intracellular localization. In this regard, perinuclear lysosomes are more acidic, rendering them the primary degradative population. Another \u223c 40% distributes along neurites of which 8% is detected in the presynaptic terminal and \u223c 26% co\u2010localizes with post\u2010synaptic markers [ 13 ] It is further noted that the endolysosomal system provides in a continuum of vesicles flowing in and out one another, also making that morphological and functional characteristics may vary within the lysosomal population; as shown recently with functional correlative microscopy (functional CLEM; [ 14 , 15 ] ). Nonetheless, there is currently little evidence for lysosomes playing a local degradative role in axons. Hence, mitophagy predominantly occurs in the soma. [ 10 , 11 ] Auto\u2010/mitophagosomes that arise in distal axons become progressively acidic upon fusion with lysosomes during retrograde transport. [ 16 ] This positions the endolysosomal system through its major role in the removal of faulty organelles and aggregates at the center of diverse processes like cellular metabolism, nutrient sensing, ion homeostasis, and local translation. With lysosomes being the end stage where all material needs to be degraded and recycled, their optimal functioning is of utmost importance. However, the late endosomal\u2010lysosomal system is often compromised in neurodegenerative conditions. In Alzheimer's disease (AD), endolysosomal compartments appear to be significantly (up to threefold) enlarged in neurons. [ 17 ] Similarly, in Parkinson disease (PD) brains, there are enlarged lysosomes with electron\u2010dense inclusion bodies and a build\u2010up of autophagosomes. [ 18 ] Lysosomal failure extends to frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) patients. Lipofuscin deposits are present in neurons and microglia in the frontal lobe of FTD patients, which is a diagnostic hallmark of lysosomal storage pathology. [ 19 ] The build\u2010up and enlargements suggest that the endolysosomal route is congested, impacting on normal function. In addition, impaired lysosomal trafficking of cathepsins has been shown in patient\u2010derived dopaminergic neurons, [ 20 ] and post\u2010mortem Parkinson brain analyses have detected lysosomes which were depleted of components like glycosphingolipids. [ 21 ] Altered expression of causal AD genes show defective lysosomal catabolism, originating from lysosomal calcium dysregulations and/or pH alkalination, an improper processing and maturation of lysosomal proteases like cathepsin D, and a cholesterol build\u2010up. [ 22 , 23 , 24 , 25 , 26 , 27 ] Cholesterol accumulation was shown to both trigger mitophagosome formation and impair lysosomal\u2010mediated clearance; demonstrating a direct link between lysosomes, mitophagy and mitochondrial health. [ 28 ] Of note, there is increasing awareness that cellular organelles, such as the ER, endosomes, lysosomes and mitochondria, interact with one another through so\u2010called membrane contact sites (MCSs). [ 29 , 30 ] As such, cellular hubs such as the endosomal system, onto which different mechanisms converge, are ideally placed to connect and propagate pathological hallmarks of neurodegeneration that would otherwise seem spatially separated and unrelated. Given the endolysosomal system plays a significant role in mitochondrial phenotypes, impacting mitophagy and overall neuronal health, we will first discuss the genetic evidence supporting a primary role for mitochondrial impairments in neurodegenerative disease and then examine how endolysosomal dysfunctions contribute to these disorders, highlighting the interplay between these organelles and their combined impact on disease progression. 2 MITOCHONDRIA DYSFUNCTION IN NEURODEGENERATION: HOW WELL SUPPORTED BY GENETICS? The mammalian mitochondrial genome is a 16.5\u2010kilobase\u2010long multicopy circular, double\u2010stranded DNA that encodes two ribosomal RNAs, 22 transfer RNAs, along with 13 protein subunits of the ETC (Figure 1 ). The presence of several forms of mitochondrial DNA (mtDNA) within an individual's cells is referred to as heteroplasmy. In contrast to nuclear DNA, which is inherited from both parents, mtDNA is inherited only from the mother. Heteroplasmy can arise for several reasons. One common cause is the presence of naturally occurring genetic variations, or polymorphisms, in the mtDNA, resulting in different versions of a particular gene within a person's cells. Another cause is the emergence of mutations. These can arise spontaneously or be inherited from the mother. Heteroplasmy levels can differ throughout tissues and even between cells within the same tissue. It is conceivable for one cell to contain a larger proportion of mutant mtDNA than nearby cells, or for none to exist at all. [ 31 ] Heteroplasmy can have various consequences depending on the mutation or polymorphism involved. Mutations that alter a crucial gene or protein involved in mitochondrial function can result in mitochondrial disorders. The severity of the disease may be determined by the fraction of mutant mtDNA found in a specific tissue or organ. [ 31 , 32 ] FIGURE 1 Mitochondrial DNA (mtDNA) structure and schematic representation of the electron transport chain. A small amount of the genetic data required for mitochondrial function is encoded on the mitochondrial chromosome, also called mtDNA (mitochondrial DNA). It contains genes required for production of proteins involved in oxidative phosphorylation and other mitochondrial processes. Protein\u2010coding genes encode various proteins involved in mitochondrial function, such as components of the electron transport chain, including subunits of cytochrome c oxidase (COX) and ATP synthase (ATPase; colors match between genes and proteins). Ribosomal RNA (rRNA) genes encode the rRNA molecules that are essential components of the mitochondrial ribosomes. They are involved in protein synthesis within the mitochondria. Thirdly, transfer RNA (tRNA) genes encode tRNA molecules, which are responsible for linking specific amino acids to the growing polypeptide chain during protein synthesis. Mitochondrial tRNAs are required for the translation of mitochondrial\u2010encoded proteins. Lastly, some non\u2010coding regions encompass regulatory elements including the control region or D\u2010loop. This region plays a role in the regulation of replication and transcription of mtDNA. It is important to note that the majority of the genes required for mitochondrial function are actually encoded by nuclear DNA (nDNA) and not on the mitochondrial chromosome itself. While there are some connections between mitochondrial protein variations/mutations and late onset Alzheimer's disease (LOAD), more research is needed to fully understand the link between AD pathophysiology and mutations in mitochondrial genes or proteins. [ 33 , 34 ] Some combinations of specific genetic variations in a person's mtDNA, referred to as one's mitochondrial (sub)haplotype, have been shown to increase the risk to develop LOAD. Where haplogroup H and cluster HV carriers display an increased risk profile, haplogroup K was detected to exert a protective, neutralizing effect in carriers of the APOE4 allele. [ 34 ] Haplogroup J carriers presented with even lower cognitive verbal resilience than haplogroup H carriers, which make up the most common group. [ 35 ] Of note, where different studies have investigated haplogroups and their link to AD risk, not all are consistent with one another in their conclusions, possibly due to the examined population demographics. [ 33 ] In addition, over half of AD brains exhibit a T414G mutation in their mtDNA, something that has not been found in healthy control brains. [ 36 ] This T414G mutation is located in the non\u2010coding control region, specifically within the D\u2010loop of the mitochondrial genome (Figure 1 ). The D\u2010loop is crucial for the regulation of mtDNA replication and transcription but does not encode any proteins directly. Though, one of the expressions it affects is of NADH dehydrogenase subunit 6 (ND6); a protein\u2010coding gene that is part of Complex I of the mitochondrial respiratory chain. [ 36 ] Hence, its reduced expression could explain the higher oxidative stress levels in AD brains. For a more comprehensive overview of the impact of oxidative stress and ageing on the development of PD or AD, we refer to Picca and colleagues. [ 37 ] Similarly, it was found that polymorphisms in the TFAM \u2010gene, which controls the transcription, replication, damage sensing, and repair of mtDNA, increases the risk to develop LOAD. [ 38 ] A stronger connection has been established in PD where for instance in the substantia nigra of PD patients, the incidence of mtDNA deletions was slightly higher than in age\u2010matched controls. [ 39 ] Notably, these deletions are specific to dopaminergic neurons and absent in other neuron types in control brains. [ 40 ] Additionally, the levels of mtDNA deletions in PD patients are significantly different from those found in brains affected by other neurodegenerative disorders [ 41 ] ; showing a clear specificity of vulnerability. Overall, dozens of mutations associated with PD are found in the mitochondrial genome; affecting in priority the subunits of complexes involved in the electron respiratory chain, for example, NADH:ubiquinone oxidoreductase core subunit 1 (ND1), [ 42 ] ND2, [ 43 ] and UQCRC1 [ 44 ] as well as support proteins, including the mitochondrially encoded 16S RNA ( MT\u2010RNR2 ). [ 45 ] To note, because of their essential function, a relatively low number of mtDNA mutations are directly causative for PD; most of them are only associated with an increased risk to develop the disease. Interestingly, these mutations correlate with the accumulation of 8\u2010oxoG, one of the most common DNA modifications caused by ROS in the mtDNA of nigrostriatal dopaminergic neurons of PD patients. [ 46 ] In response, dopaminergic neurons overexpress the 8\u2010oxoG DNA glycosylase mitochondrial isoform to reduce the DNA damage caused by oxidative stress. [ 47 ] Several brain regions of PD patients also demonstrate increased mtDNA modifications, suggesting that mitochondrial damage is not restricted to the substantia nigra . [ 41 ] This buildup of mtDNA modifications in the remaining part of the brain could also be important for the development of neurodegeneration and the slow development of PD. In contrast to PD and AD, where there is clear evidence of dysfunction or decreased metabolism in the mitochondrial respiratory chain, there have been limited biological observations indicating mitochondrial dysfunction in sporadic cases of FTD or ALS. Arguably, the scientific literature lacks to find a consensus on the role of mtDNA in the pathogenesis of these disorders. While some studies have found no correlation between mitochondrial haplogroups in ALS [ 48 ] or FTD, [ 49 ] recent study cases and larger research studies suggest that a mutation in the ND5 gene of mtDNA (Figure 1 ) might contribute to the heritability of ALS. [ 50 ] Similarly, a mtDNA mutation in the ND4 gene (Figure 1 ), typically associated with Leber's hereditary optic neuropathy, was found concurrently in two ALS patients, [ 51 ] and the common mtDNA deletion mutation (mt DNA4977) was identified 30 times more frequently in the brains of ALS patients compared to healthy controls. [ 52 ] Furthermore, an association between a mtDNA mutation in the ND1 gene (Figure 1 ) and disease has been reported in an FTD patient. [ 53 ] Dual sequencing techniques have revealed that the temporal lobes of FTD patients exhibit elevated levels of single nucleotide variants (mtSNVs) and rearrangements within their mtDNA structure, along with an increased heteroplasmy. Notably, ribosomal genes have shown a higher prevalence of gene variants impacting intra\u2010mitochondrial protein synthesis, while respiratory chain subunits have demonstrated a greater proportion of missense variants. [ 54 ] Of note, among the few strong indications for a mitochondria\u2010driven etiopathology are the mutations in the superoxide dismutase 1 ( SOD1 ) gene that have been linked to familial ALS. [ 55 , 56 ] This cytoplasmic antioxidant enzyme protects against oxygen toxicity by breaking down superoxide radicals into molecular oxygen and hydrogen peroxide. Where SOD1 is located on chromosome 21q22.11, the aggregation of mutant SOD1 occurs both in the cytoplasm and in the mitochondria and it is generally accepted that the primary cause of mutant SOD1 toxicity is mitochondrial malfunction. [ 57 ] In this regard, Pedrini and colleagues showed that the toxicity of mutant SOD1 is dependent on its interaction with BCL2 in a spinal cord mitochondria\u2010specific manner. It produces morphologic alterations and reduces mitochondrial membrane integrity, leading to the release of cytochrome c exclusively in the presence of the integral outer mitochondrial membrane protein BCL2. [ 58 ] Mitochondrial disruption also leads to other pathological (rescue) mechanisms, as we will discuss below. Hence, while the higher prevalence of heteroplasmic mtDNA variants seems crucial in influencing susceptibility of disease development, mounting evidence indicates different other dysfunctions to disrupt the delicate balance between mitochondrial quality control mechanisms, leading to a decline in mitochondrial fitness and overall cellular health. 3 REGULATION OF MITOCHONDRIAL FITNESS AND TURNOVER 3.1 Mitochondrial defects routed in a defective clearance\u2014mitophagy Autophagy, which translates as \u201cself\u2010eating\u201d in Greek, refers to mechanisms that break down and remove cell components and organelles, including mitochondria, by delivering them to the lysosome. The process can be either basal\u2010 or stress\u2010induced, [ 59 ] making autophagy to have a genuine role in normal biology, while being obviously elevated upon cellular stress as in neurodegenerative disorders but also cancer. Some open questions in the fields were recently discussed in an editors' corner. [ 59 ] Mitophagy specifically is initiated through 1 of the following 3 pathways, (1) cardiolipin\u2010mediated, (2) receptor\u2010mediated, or (3) ubiquitin\u2010mediated (Figure 2 ). FIGURE 2 The principal mechanisms of mitophagy. These include (I) lipid\u2010mediated mitophagy, mainly initiated by cardiolipin transfer from the inner mitochondrial membrane (MM) during the process of mitophagy (II) In receptor\u2010mediated mitophagy, outer MM receptors such as FKBP8 bind directly to LC3s, allowing for the formation of a mitophagosome (III) Lastly, ubiquitin\u2010mediated mitophagy consists of two pathways: PINK1\u2010Parkin\u2010dependent mitophagy and Parkin\u2010independent mitophagy. During PINK1\u2010Parkin\u2010dependent mitophagy, PINK1 accumulates on the outer MM and recruits Parkin from the cytosol to the outer MM. This leads to the phosphorylation and ubiquitination of proteins on the outer MM, ultimately resulting in the formation of the mitophagosome. In Parkin\u2010independent mitophagy, other E3 ubiquitin ligases like MUL1, are at play. The lethality and detrimental effect of not having a proper working mito/autophagic system is well illustrated by the fact that there have only been few reports of genetically inherited harmful variants in core autophagy\u2010related genes in human patients. Most notably was the detection of an amino acid substitution in ATG5, causing congenital ataxia with mental retardation. The pathology is grounded in a hindered autophagic flux. [ 60 ] There are further some pathologies linked to mutations in the WIPI (WD\u2010repeat protein Interacting with PhosphoInositides) family, including WIPI2, [ 61 ] WIPI3, [ 62 ] and WIPI4, [ 63 ] important initiators that bind phosphoinositides and recruit autophagy proteins, which all have some form of neurological deficit. Pathologies associated with more downstream autophagy defects include Vici syndrome. It is caused by recessive mutations in EPG5, a Rab7 effector that regulates fusion specificity between autophagosomes with late endosomes/lysosomes [ 64 ] and causing the mitochondria population to display an irregular shape and spreading. Lastly, there are optineurin and p62 as well as their upstream regulator tank\u2010binding kinase 1 (TBK1) that are linked to ALS development. [ 65 ] Nonetheless, several neurodegenerative diseases have been associated with disruptions in the mitophagy process, contributing to the accumulation of defective mitochondria and subsequent cellular dysfunction. For instance, PD is linked to impaired mitophagy, as key proteins involved in this process, such as the ubiquitin ligase Parkin ( PARK2 ) and protein kinase PINK1 ( PARK6 ), are mutated in rare familial forms of the disease; both are key players involved in targeting damaged mitochondria for mitophagy. [ 66 ] Similarly, mutations or depletion in the CHCHD10 gene, primarily mutated in the spectrum of ALS/FTD, disrupt the PARL\u2010PINK1 pathway and, hence, impair mitophagy in patients\u2019 brain. [ 67 ] This failure of mitochondrial turnover ultimately leads to TDP\u201043 aggregation, creating a negative feedback loop; indeed TDP\u201043 aggregation in return induces mitochondrial damage by decreasing the mitochondrial membrane potential, increasing ROS production and the accumulation of defective endosomes. [ 68 ] Further, different PD\u2010linked risk factor genes are functioning in phagophore formation up to lysosomal functioning, including for the removal of mitochondria. The ubiquitin ligase substrate receptor FBXO7/PARK15 is mutated in an early\u2010onset parkinsonian\u2010pyramidal syndrome and shown to directly interact with the aforementioned PINK1 and Parkin to promote mitochondrial clearance through a feed\u2010forward process involving ubiquitin phosphorylation. [ 69 ] More recently Kraus and colleagues did not detect any discernible changes in mitochondria or other organelles in FBXO7/PARK15 knockout cells, but rather detected a biochemical association between SKP1\u2010FBXO7 and PSMF1. [ 70 ] Being a negative regulator of the proteasome, this suggests the role of FBXO7/PARK15 could not lie in mitophagy but in modulating proteasomal activity. Mutations in PARK7, encoding DJ\u20101, are also associated with early\u2010onset familial PD. DJ\u20101 is an essential downstream mediator in PINK1/parkin\u2010dependent mitophagy. [ 71 ] The fusion of the autophagosome with the lysosome is a next crucial step in the autophagic flux, facilitating the degradation of autophagosomal contents. The coordination of autophagosome\u2010lysosome fusion is pivotal for proper cellular function and is tightly regulated to ensure efficient removal of cellular debris. Variants in the endocytic protein PICALM, which stands for phosphatidylinositol binding clathrin assembly protein, have been linked to an elevated risk to develop LOAD, [ 72 ] PD, [ 73 ] and FTD. [ 74 ] It is known to be involved in various stages of autophagy by regulating the endocytosis of SNARE proteins, such as VAMP2, VAMP3 and VAMP8, which are all involved in different steps in the autophagy process. [ 75 ] When PICALM dysfunctions, autophagosome formation is hindered by a decrease in the fusion of precursor vesicles; a process that relies on VAMP2 and VAMP3. Additionally, PICALM knockdown affects the VAMP8\u2010mediated fusion of autophagosomes with lysosomes. Consequently, a deficiency in PICALM results in a reduction in the autophagic flux. The latter may be confounded by the effect PICALM has on lysosomes, enabling the processing and maturation of the lysosomal proteases as cathepsin D. [ 22 ] Another protein of interest is the ubiquitin\u2010like protein UBQLN1 that participates in autophagosome\u2010lysosome fusion most likely through interaction with ATG8E (MAP1LC3A). [ 76 ] Polymorphisms have been associated with an increased risk to develop LOAD [ 77 ] and ALS/FTD, [ 78 ] it was found to regulate pathological synucleinopathies, [ 79 ] and its overexpression reduces the number of A\u03b2 plaques in mouse hippocampi as well as improves their cognitive performance. [ 80 ] Its impact in autophagy may also be confounded by the positive correlation between functional UBQLN1 and BACE1 protein levels, the major endosomal \u03b2 secretase for the generation of A\u03b2 peptides. [ 81 ] The stabilization of BACE1 protein levels by UBQLN1 potentially occur through a mechanism involving decreased degradation in the lysosomal compartment. [ 82 ] The importance towards these mechanisms is demonstrated by the large number of mitochondrial proteins to be enriched in the cytoplasm of UBQLN1 depleted cells. [ 83 ] Alterations in endolysosomal processes can further be reciprocally triggered by mitochondrial abnormalities. Endolysosomal biogenesis is increased or decreased in response to an acute or chronic mitochondrial assault. [ 84 ] It was shown that both the functionality and shape of lysosomes can be disrupted by mitochondrial malfunction, produced by exposure to mitochondrial toxins or the deletion of mitochondrial\u2010related proteins such as apoptosis\u2010inducing factor (AIF), PINK1, and Parkin. [ 85 ] Also in AD, the accumulation of dysfunctional mitochondria was shown to further aggravate the degradative bottleneck. AD\u2010affected neurons present with a loss of mitochondrial potential that leads to the disintegration of the microtubule network and, hence, disruption of the autophagic flux to lysosomes. [ 86 ] In addition, oxidative stress caused by A\u03b2 can interfere with the mobility and functionality of mitochondria. [ 87 ] This sets up a negative feedback loop in which A\u03b2 increases mitochondrial dysfunction that, in turn, worsens A\u03b2 production and accumulation. mtDNA\u2010induced mitochondrial failure also increases tau oligomer levels and shifts the oligomer\u2010monomer equilibrium towards the oligomer state. [ 88 ] Similarly, a reduced lysosomal capacity (Table 1 ), associated with a decline in degradative functions, is connected to compromised mitophagy in PD, leading to the build\u2010up of damaged mitochondria. [ 89 ] TABLE 1 Endolysosomal genes associated with neurodegeneration. Gene Protein Location Function Disease OMIM identifier APOE Apolipoprotein E Recycles in endosomes\u2010lysosomes Lipid transport AD, PD, FTD 107741 ASAH1 N\u2010acylsphingosine amidohydrolase Lysosomes Degrades ceramide into sphingosine and free fatty acids Spinal muscular atrophy, Farber lipogranulomatosis 613468 ATP10B Atpase, Phospholipid\u2010transporting, 10B Lysosomes Translocate aminophospholipids from the exoplasmic (luminal) leaflet to the cytoplasmic leaflet of lipid bilayers PD 619791 ATP13A2 ( PARK9 ) ATPase cation transporting 13A2 Endosomes, lysosomes Transports inorganic cations and other substrates across membranes AD, ALS, Kufor\u2010Rakeb, Spastic paraplegia 610513 BIN1 Myc box\u2010dependent\u2010interacting protein 1 (Recycling) Endosome Regulation of intracellular vesicle sorting AD, Centronuclear myopathy 2 601248 C9orf72 Guanine nucleotide exchange factor C9orf72 Lysosome Has guanine nucleotide exchange factor (GEF) activity and regulates autophagy ALS, FTD 614260 CD2AP CD2\u2010associated protein (Recycling) Endosome Anchor between membrane proteins and actin cytoskeleton AD 604241 CHMP2B Charged multivesicular body protein 2b Autophagosome, Lysosome MVB Component of the endosomal sorting required for transport complex III (ESCRT\u2010III) ALS, FTD 609512 CLCN3 H(+)/Cl(\u2010) exchange transporter 3 Endosome, Lysosome Supports luminal acidification PD, Schizophrenia 600580 CTSB Cathepsin B Lysosome Cysteine protease that cleaves i.a. the amyloid beta peptide AD, PD 116810 CTSC Cathepsin C Lysosome Thiol protease, dipeptidylpeptidase FTD 602365 CTSD Cathepsin D Lysosome Aspartyl protease, substrates include \u03b1syn, APP & tau AD, ceroid lipofuscinosis, PD 116840 CTSH Cathepsin H Lysosome Hydrolysis of proteins AD 116820 DGKQ Diacylglycerol kinase theta Endosome Converts diacylglycerol into phosphatidic acid AD, PD 601207 DNAJC6 Putative tyrosine\u2010protein phosphatase auxilin Endocytic vesicle Clathrin\u2010mediated endocytosis PD 608375 DOC2A Double C2\u2010like domain\u2010containing protein alpha Lysosome Calcium sensor, regulates membrane fusion AD 604567 GBA Acid beta\u2010glucocerebrosidase Lysosome Degrades the glycolipid glucosyl\u2010ceramide to ceramide and glucose Gaucher disease, PD 606463 GALC Galactosylceramidase Lysosome Breakdown of galactose ester linkages within glycolipids Krabbe disease (PD) 606890 GLA Alpha\u2010galactosidase Lysosome Breaks down glycolipids and glycoproteins' terminal alpha\u2010galactosyl moieties by hydrolysis Fabry disease, PD 300644 GRN Progranulin Lysosome Controls protein transport to lysosomes and the activation of lysosomal enzymes AD, ALS, ceroid lipofuscinosis, FTD, PD 138945 GPNMB Glycoprotein NMB Early endosome Involved in cell differentiation, migration, inflammation, tissue regeneration, and neuroprotection AD, PD, Nasu\u2010Hakola disease 604368 GUSB Beta\u2010glucuronidase Lysosome Sequential breakdown of glycosamino\u2010glycans containing glucuronic acid PD, Sly syndrome 611499 IDUA Alpha\u2010L\u2010iduronidase Lysosome Hydrolysis of unsulfated alpha\u2010L\u2010iduronosidic linkages in dermatan sulfate AD, Mucopolysaccharidosis 252800 INPP5F Phosphatidylinositide phosphatase SAC2 (Recycling) Endosome Inositol 4\u2010phosphatase, role in endocytic recycling AD, PD 609389 LRRK2 Leucine\u2010rich repeat kinase 2 Lysosome Serine/threonine\u2010protein kinase that phosphorylates proteins involved autophagy, vesicle trafficking, innate immunity, and neural plasticity PD 609007 MAPT Microtubule\u2010Associated Protein Tau Cytosol, Lysosomal clearance Promotes microtubule assembly and stability AD, FTD, PD, Pick disease, supranuclear palsy 157140 NEU1 Neuraminidase Lysosome Catabolism of sialated glycoconjugates PD, Sialidosis 608272 OPTN Optineurin Autophagosome, (Recycling) Endosome Adaptor protein involved in endocytic trafficking ALS, FTD, Huntington's disease 602432 PICALM Phosphatidylinositol\u2010binding clathrin assembly protein Endocytic vesicle Role in SNARE endocytosis, maturation of autophagic precursors AD, FTD, PD 603025 PLD3 Phospholipase D3 Lysosome 5\u2032\u22123\u2032 exonuclease AD, spinocerebellar ataxia 615698 PSEN1 Presenilin 1 Plasma membrane (lysosome) Catalytic component of gamma\u2010secretase AD, FTD, Niemann\u2010Pick disease 104311 PSEN2 Presenlin 2 Endosome, Lysosome Catalytic component of gamma\u2010secretase AD 600759 RIN3 Ras and Rab interactor 3 Endocytic vesicle, Endosome Exchanges bound GDP for free GTP AD 610223 SCARB2 Scavenger Receptor Class B Lysosome Acts as a lysosomal receptor for glucosylceramidase (GBA1) targeting PD 602257 SH3GL2 Endophilin\u2010A1 Endocytic vesicle, Endosome Involved in synaptic vesicle endocytosis PD 604465 SLC17A5 Sialin Lysosome Free sialic acid exporter from lysosomes PD, Salla disease 604322 SMPD1 Sphingomyelin phosphodiesterase 1 Lysosome Converts sphingomyelin to ceramide, role in the export of cholesterol Niemann\u2010Pick disease, PD 607608 SYNJ1 Synaptojanin 1 Endocytic vesicle Polyphosphoinositide phosphatase with a role in clathrin\u2010mediated endocytosis Developmental/epileptic encephalopathy, PD 604297 SYT11 Synaptotagmin 11 Endosome, lysosome Regulating endocytosis, the vesicle\u2010recycling process and the ATP13A2\u2010linked autophagy\u2010lysosome pathway PD 608741 TLR9 Toll\u2010like receptor 9 Lysosome Detects unmethylated CpG dinucleotides AD 605474 TMEM106B Transmembrane Protein 106B Lysosome Transport of late endosomes/lysosomes AD, ALS, FTD 613413 TMEM175 Transmembrane Protein 175 Endosomes, lysosomes K(+)\u2010selective channel, regulates lysosomal pH stability and organelle fusion PD 616660 TPCN1 Two pore channel protein 1 Early and recycling endosomes Voltage\u2010gated Ca(2+) and Na+ channel, senses pH changes AD 609666 VAMP4 Vesicle\u2010Associated Membrane Protein 4 Endosome Trafficking protein PD 606909 VPS13C ( PARK23 ) Vacuolar protein sorting 13 homolog c Lysosome Facilitates the transfer of lipids between membrane contact sites PD 608879 VPS35 Vacuolar protein sorting\u2010associated protein 35 Endosome Component of the retromer cargo\u2010selective complex PD 601501 WDR81 WD repeat\u2010containing protein 81 Endosomes Inhibits PtdIns3 kinase, permitting loss of PtdIns3P and conversion of early to late endosomes AD, Cerebellar Ataxia 614218 John Wiley & Sons, Ltd. 3.2 An endolysosomal demise in neurodegenerative diseases The endolysosomal system is a dynamic network of vesicular and tubular structures that facilitates the trafficking of cargo towards recycling or degradation. By removing misfolded proteins, damaged organelles, and other cellular waste, this mechanism is essential to maintaining cellular integrity particularly in a neuronal and brain context. There is growing evidence that in neurodegenerative diseases, the endolysosomal system is resulting in functional impairments, in particular under pressure. [ 90 , 91 ] One of the hallmarks of neurodegenerative diseases is the accumulation of protein aggregates, such as \u03b2\u2010amyloid in AD, \u03b1\u2010synuclein in PD or TDP\u201043 in FTD. These aggregates not only disrupt normal cellular function but also present a formidable challenge to the endolysosomal system. The overwhelmed lysosomes struggle to efficiently degrade these protein aggregates, leading to their accumulation within neurons and subsequent toxicity. This failure in protein clearance mechanisms not only promotes the spread of pathological protein species but also triggers a cascade of cellular events that contribute to neuroinflammation, synaptic dysfunction, and ultimately neuronal demise. In support, genetic variants associated with neurodegenerative diseases more often intersect with genes involved in the regulation of the endolysosomal system (Table 1 ). Whereas not all proteins have been linked to dysregulations in each neurodegenerative disorder, the diverse set of endosomal proteins (1) underscores a generalized malfunctioning of the system, and (2) may reflect as well cell\u2010type specific vulnerabilities specific to different neurodegenerative diseases. These mutations disrupt the delicate balance of endolysosomal dynamics, impairing the trafficking of critical proteins and compromising the lysosomal degradation machinery. This indirectly affects mitochondrial health through amongst others destabilized lysosome\u2010mitochondria contact sites. [ 92 ] A good example of the interconnection between different proteins and disease is the human apolipoprotein E4 isoform (APOE4), one of the strongest genetic risk factors for LOAD. Despite activating macroautophagy, APOE4\u2010carrying cells exhibit an enhanced lysosomal trafficking and an APOE4 accumulation in enlarged lysosomes, indicating again poor clearance. [ 93 ] This deregulation affects the amount of autophagy proteins and lipid droplets (LDs), and changes the proteomic contents of lysosomes after internalization. [ 93 ] Interestingly, homozygote carriers of APOE4 also present with more mitochondrial network fragmentation that can be traced back to the promoted mitophagy. [ 94 ] APOE4 affects membrane lipid contents and, as such, communication with mitochondria through MCSs. [ 95 ] The functioning of APOE, including its ability to bind A\u03b2, relies on lipidation; a function carried out by another LOAD risk factor protein ABCA1. [ 96 ] Zhao and colleagues observed a lower lipidation status in APOE4 carriers compared to those with APOE3. [ 97 ] Additionally, different independent studies detected a deficiency in ABCA1 to increase A\u03b2 deposition and cerebral amyloid angiopathy, and lower basal cognition. [ 98 , 99 ] Interestingly, ABCA1 deficiency affects A\u03b2 clearance and cognition in APOE4\u2010expressing mice but not in APOE3\u2010expressing mice. [ 100 ] This effect on APOE and the endolysosomal system may contribute to ABCA1 defects negatively regulating mitophagy following mitochondrial damage in a PINK1/Parkin\u2010independent way. [ 101 ] While not an endolysosomal protein itself, the above points to a probable interaction between different genetic risk factors. This is even more of importance with the APOE \u03b54 allele being recently identified as a major risk factor for the conversion to PD dementia [ 102 ] and there to be a genotype\u2010specific effect of APOE on TDP\u201043 proteinopathy. [ 103 ] For instance, levels of different LOAD risk genes, including APOE, clusterin (CLU) but also SORLA (Sortilin\u2010related receptor with LDLR class A repeats) correlate in human brain in neurons. [ 104 ] SorLA levels are also lowered in the anterior horn cells of ALS patients. [ 105 ] SORLA is mostly known for playing a role in the endosomal sorting/recycling of three transmembrane proteins linked to AD pathophysiology: APP, the BDNF receptor Tropomyosin\u2010related kinase B, and the glutamate receptor subunit AMPA1. [ 106 ] Human excitatory neurons lacking SORL1 exhibit APP\u2010dependent deficiencies in the endolysosome\u2010autophagy network [ 107 ] ; including mitophagy. SORL1 was shown to have a subtle impact on mitochondrial function and iron homeostasis linked to gene expression alterations linked to i.a. the mTORC1 signalling pathway. [ 108 ] SORL1 KO and SORL1 G511R neurons were shown to have different lipid profiles. [ 104 ] CLU is a highly conserved glycoprotein that functions as a molecular chaperone and has gained significant attention in the field of AD research. Its levels show a positive correlation with A\u03b2 load. [ 109 ] Despite this increase, the concentration of A\u03b242 does not rise in proportion. As a result, the ratio of CLU to A\u03b242 decreases in these regions, which potentially encourages the accumulation of amyloid within the tissue. [ 109 ] Indeed, CLU exhibits a strong binding affinity towards A\u03b21\u201042 oligomers and effectively hinders the aggregation of the peptide by inhibiting both primary and secondary nucleation. [ 110 ] Secreted CLU also promotes autophagy through the AMPK/Akt/mTOR signaling pathway, [ 111 ] while cytosolic CLU drives misfolded proteins to the proteasome and autophagosomes by forming stable complexes with them. [ 112 ] While not yet investigated in a neuronal context, gain\u2010of\u2010function and loss\u2010of\u2010function experiments involving CLU revealed its specific involvement in the process of mitophagy. [ 113 ] Additionally, CLU was found to regulate mitochondrial fission by activating the Ser/Thr kinase AKT. This activation leads to the phosphorylation of DNM1L/Drp1 at the serine 616 residue, resulting in mitochondrial fission. [ 113 ] Aside from the APOE\u2010CLU\u2010SORLA cluster in AD, we highlight here as well the link between the GBA and SCARB2 pair. Mutations in these genes have been found associated with rare cases of early onset PD, but also dementia with Lewy Bodies (DLB). [ 114 ] GBA encodes the lysosomal enzyme glucocerebrosidase (GCase), which is involved in sphingolipid metabolism. The subsequent changes in lysosomal lipids generated by GBA deficiency build up lysosomal dysfunction, chaperone\u2010mediated autophagy insufficiency, and \u03b1\u2010synuclein pathology. [ 115 ] Mutant GCase in the lysosome reduces the levels of ceramides, which are for instance necessary to promote cathepsin maturation. This leads to a slower turnover and increased amounts of \u03b1\u2010synuclein, and hence a higher chance of developing PD. Given an \u03b1\u2010synuclein build\u2010up to also interfere with any remaining GCase activity, this results in a self\u2010reinforcing loop. [ 116 ] SCARB2 (Scavenger Receptor Class B Member 2), also known as LIMP\u20102, is an endomembrane member of the CD36 superfamily of scavenger receptors that targets Gcase to the lysosomes. [ 117 ] It was recently shown to be involved as well in lysosomal cholesterol export by working in tandem with Niemann Pick (NPC)\u2010proteins. [ 118 ] Aside from the NPC\u2010 and GBA\u2010linked downstream effects, cells depleted of SCARB2 were shown to exhibit an impaired OXPHOS that was mTORC1\u2010induced. [ 119 ] Loss\u2010of\u2010function mutations in ATP13A2, a lysosomal polyamine transporter, [ 120 ] are causally linked to a broader spectrum of neurodegenerative diseases, including Kufar\u2010Rakeb syndrome, early onset PD, neuronal ceroid lipofuscinosis, hereditary spastic paraplegia and ALS. [ 121 ] ATP13A2 deficiency causes mitochondrial dysfunction through impaired lysosomal function originating from accumulating polyamines and a loss of their cytoprotective role in counteracting mitochondrial oxidative stress. [ 122 ] Lastly, variants of the lysosomal Transmembrane protein 106B (TMEM106B) have been linked to increased risk for FTD, [ 123 ] whereas TMEM106B may also function as a genetic modifier for the cognitive trajectory in PD. [ 124 ] It has been shown to promote Arl8b\u2010mediated lysosomal trafficking and, hence, autophagosome to autolysosome maturation. Its loss\u2010of\u2010function blocks the autophagic flux, and impairs lysosomal functions. [ 125 , 126 ] Besides, altered TMEM106B levels may affect as well TFEB levels and its mTOR\u2010dependent nuclear (trans)location. [ 127 ] The primarily lysosomal defects consequently affect downstream mitochondrial health, eventually leading to caspase\u2010dependent mitochondrial cell death. [ 127 ] The broader claim that abnormalities in other organelles can cause mitochondria malfunction is emphasized recently in a multi\u2010omics profiling study demonstrating that organelle defects alter cell\u2010wide organelle interactions and communication with a repercussion on mitochondrial structure and function. [ 128 ] Another more recent example relates to the BLOC\u2010one\u2010related complex (BORC), wherein mutations in one of its subunits give rise to early\u2010infantile neurodegenerative disorder. [ 129 ] BORC functions in recruiting the small GTPase ARL8 and kinesin motor proteins to promote axonal anterograde transport. However, lysosomal vesicles also play a critical role in the transport of axonal mRNAs, including a subset encoding ribosomal and mitochondrial/OXPHOS proteins. Knock\u2010out of BORC, resulted in a depletion of these mRNAs in distal axons, leading to mitochondrial defects, and ultimately axonal degeneration. [ 130 ] 3.3 Downstream pathways activated by lysosomal dysfunction: The case of cGAS\u2010STING A failure in mitophagy, directly or indirectly caused by lysosomal dysfunction, will lead to the accumulation of partially degraded mitochondria in autophagolysosomes (Figure 3 , [ 92 ] ). This could potentially worsen a degradation bottleneck by at least two mechanisms. Firstly, mitochondria have a double membrane and failure to properly degrade mitochondria will lead to a congestion of membranes in autolysosomes. This could explain the parallel appearance of multilamellar bodies, as observed in PLD3\u2010linked LOAD, [ 92 ] brains of a PS/APP mice, [ 131 ] GBA\u2010Parkinson disease, [ 132 ] or SOD1 G93A \u2010ALS. [ 133 ] Indeed, an auto/mitophagic vacuole has been subscribed to be an environment favorable for the production of membrane lamella as a result of selective resistance to lysosomal breakdown. [ 134 ] Secondly, mtDNA will readily accumulate and instigate downstream signalling pathways of different kinds, including autophagy/mitophagy\u2010inducing pathways that bring extra debris to an already congested system. [ 92 ] mTOR signalling can be induced by lysosome\u2010localized, DNA\u2010triggered TLR9 activation [ 90 ] ; of particular interest with TLR9 being another LOAD risk factor. [ 135 ] In addition, congested lysosomes or not\u2010cleared damaged mitochondria can also directly release mtDNA into the cytosol where it activates the cGAS\u2010STING pathway. FIGURE 3 The interplay between lysosomal function and mitochondrial health. The top panel depicts a healthy cellular state in which lysosomes efficiently degrade cellular waste and damaged mitochondria via autophagy. The mitochondria, through the TCA cycle, generate ATP and provide essential metabolites for lipid and cholesterol synthesis, as well as other cellular processes. In case of a lysosomal catabolic bottleneck (bottom panel), compromised lysosomal activity results in a hindering of the autophagic flux and the accumulation of damaged mitochondria. Similarly to lysosomes, leaky mitochondria release free cytosolic DNA, which activates the cGAS\u2010STING pathway, leading to type I interferon responses (IRF3) and inflammation. In parallel, this cascade of events results in reduced energy supply, NAD+ depletion, and increased reactive oxygen species (ROS) damage, further exacerbating lysosomal dysfunction. The interactions between affected mitochondria and lysosomes illustrate the bidirectional relationship where impaired lysosomal function hinders the removal of defective mitochondria, and vice versa, highlighting the critical need for maintaining the integrity of both organelles for cellular health. The cGAS\u2010STING pathway detects cytoplasmic DNA, which can be an indicator of viral or bacterial infection as well as of stress\u2010linked (mt)DNA leakage. [ 136 ] cGAS (cyclic GMP\u2010AMP synthase) is a cytosolic DNA sensor that identifies DNA and activates cyclic GMP\u2010AMP (cGAMP) synthesis. This secondary messenger binds to STING (stimulator of interferon genes) that translocates to the Golgi and causes downstream signaling pathways to be activated (Figure 3 ); inducing autophagy/mitophagy and producing type I interferons and other pro\u2010inflammatory cytokines. The deregulation of the cGAS\u2010STING pathway has been linked to a variety of different neurodegenerative diseases as well as age\u2010related dysfunctions. STING activation can occur through leakage of DNA from (damaged) mitochondria or lysosomes. Increased lysosomal leakiness is observed in relation to several neurodegenerative disease models. In neurons, this pathway primarily activates autophagy, contributing to a bottleneck in autophagic and mitophagic processes. [ 92 ] APP/PS1 mutant and 5\u00d7FAD mice show lysosomal accumulation of APP fragments and cGAS\u2010STING pathway activation, while cGAS \u2212/\u2212 5\u00d7FAD animals are protected against amyloid\u2010\u03b2 pathology and cognitive decline. [ 137 , 138 ] Similarly, other APP\u2010linked metabolism changes were associated to an increased lysosomal membrane leakage in a PLD3\u2010linked cellular LOAD model [ 92 ] and in PGRN\u2010deficient microglia. [ 139 ] Lysosomal membrane damage and associated leakage have been observed in Niemann\u2010Pick type C disease [ 140 , 141 , 142 ] and VCP\u2010related FTD and ALS, [ 143 ] with lysosomal rupture caused by 4R tau build\u2010up. [ 143 ] Lysosomal repair mechanism defects in ALS\u2010associated mutations and PD\u2010linked LRRK2 risk genes exacerbate dysfunction, impacting processes such as LYTL (Lysosomal Tubulation/sorting driven by LRRK2). [ 144 , 145 ] Another example is LAMP3, which links to a PD risk locus in both Asian and Caucasian populations. [ 146 ] Unlike LAMP1, LAMP3 is not constitutively expressed, and its aberrant expression degrades LAMP1, increasing lysosomal membrane permeabilization and cathepsin leakage, thus disrupting autophagic flux. [ 147 ] Of note, the lysosomal congestion implies besides proteins also metabolites and lipids. Loss\u2010of\u2010function mutations in the P5B\u2010type ATPase and the lysosomal polyamine exporter ATP13A2 (PARK9) lead the accumulation of polyamines, ultimately contributing to lysosomal rupture. [ 120 ] Cholesterol accumulation enhances the leakage from lysosomes in NPC1\u2010linked Niemann\u2010Pick Type C [ 140 ] and PLD3\u2010linked LOAD, [ 92 ] while a build\u2010up of sphingomyelin causes lipid\u2010induced lysosomal damage in Niemann\u2013Pick disease type A. [ 148 ] Interestingly, these alterations to membrane lipid compositions also affect the interactions between different cellular organelles (vide infra). Mitochondria can also leak mtDNA directly to the cytosol. [ 143 , 149 , 150 ] For instance, in the context of ALS/FTD, TDP\u201043 has been shown to invade mitochondria inducing DNA release via the permeability transition pore. [ 150 ] A similar mitochondrial damage and release mechanism was described in an SOD1 ALS model, [ 143 ] and possibly in a model of A\u03b2 pathology in which inhibiting Cyclophilin D, a key component in the permeability transition pore, reduced inflammation. [ 151 ] The absence of Parkin or PINK1 triggers a STING\u2010mediated type I IFN response accelerating the development of dementia or systemic autoimmunity. [ 152 ] Similarly, \u03b1\u2010synuclein (\u03b1Syn) pathology causes STING\u2010dependent neuroinflammation and dopaminergic neurodegeneration in a mouse model of PD. [ 153 ] It has also been shown that \u03b1Syn itself may accumulate in mitochondria of dopaminergic neurons, leading to a reduced electron transport chain activity, an overproduction of ROS [ 154 ] and increased mitophagy levels. [ 155 ] The increased cellular stress promotes in turn more mitochondrial import of \u03b1Syn, creating a negative feedback loop to a point where the lysosomal system is unable to sustain the increasing turnover of damaged mitochondria. [ 156 , 157 ] A similar cascade of events has been found for the SOD1 G93A mutant, [ 158 ] underscoring similarities between distinct etiopathologies. There is an interesting parallel with normally aged cells. Gulen and colleagues demonstrated that mitochondria leak mtDNA into the cytosol of aged microglia. [ 159 ] These aged microglia showed lowered expression of lysosomal MAC3 when STING was suppressed, [ 159 ] indicating lysosomal involvement even though they were not the primary etiology. 3.4 An emerging role for a failing inter\u2010organellar communication in neurodegeneration Another mechanism by which endolysosomal dyshomeostasis may compromise mitochondrial fitness could originate from a disrupted inter\u2010organellar communication through MCSs. In general, MCSs enable organelles to directly exchange lipids, ions and metabolites in order to rapidly respond to environmental and developmental changes (Figure 4 ; [ 29 , 160 , 161 ] ). Lysosomal dysfunction could compromise normal functioning of MCSs with different organelles, in this way propagating defects to other subcellular compartments. With many neurodegenerative diseases displaying both endolysosomal and mitochondrial dysfunctions, and neurons depending profoundly on robustly regulated lysosomal and mitochondrial homeostasis, attention is increased towards lysosome\u2010mitochondrial (lyso\u2010mito) MCSs. This had led to the identification of functional components (reviewed in [ 29 , 162 ] ). For instance, the hydrolysis of Rab7GTP by its GTPase activating protein TBC1D15 on the mitochondria regulates lyso\u2010mito untethering. [ 163 ] Interestingly, mutations in Rab7 linked to Charcot\u2010Marie\u2010Tooth type 2B disease (CMT2B) increase lyso\u2010mito contact duration, causing general mitochondrial network impairments. [ 164 ] Other factors involved in lyso\u2010mito MCS function, such as GDAP1 and mitofusin 2 are mutated in CMT type 2K and 2A, respectively, [ 165 , 166 ] in these cases underscoring a strong genetic basis for mitochondrial dysfunction driving certain peripheral neuropathies. FIGURE 4 Lyso\u2010Mito Membrane Contact Sites (MCSs). The schematic representation of molecular interactions at MCSs between lysosomes and mitochondria. Key components involve TRPML1, a lysosomal cation channel responsible for Ca 2 \u207a transfer to mitochondria, and VDAC1, a mitochondrial channel. Cholesterol and iron are also exchanged at these sites. Other important proteins such as LAMP1, RAB7, GDAP1, and VPS13A play crucial roles in maintaining the structural and functional integrity of these contacts, ensuring efficient lipid and ion transfer necessary for cellular homeostasis. The electron microscopy image on the right showcases the physical proximity of lysosomes (Lys) and mitochondria (Mito) within the cell. The arrows indicate the close contact points, highlighting the regions where inter\u2010organellar communication occurs. The scale bar represents 500 nm. Lyso\u2010mito MCSs also play critical roles in the exchange of ions and metabolites, involving several proteins wherein mutations are linked to lysosomal storage diseases that include neurodegeneration. For instance mutations in the lysosomal cation channel TRPML1 cause mucolipidosis type IV. [ 167 ] TRPML1 has been shown to mediate also Ca 2+ transfer to mitochondria through MCSs and loss\u2010of\u2010function mutations indeed decrease mitochondrial Ca 2+ uptake and affect lyso\u2010mito MCSs. [ 167 ] Another example is Niemann\u2010Pick type C (NPC) that is characterized by a progressive neurodegeneration and caused by NPC1 gene mutations. The corresponding protein is implicated in cholesterol egress from late endosomes and lysosomes, [ 168 ] and its dysfunction impacts mitochondria through for instance altering the number of lyso\u2010mito MCSs. [ 169 ] Also for major neurodegenerative diseases like PD, ALS and AD, a derailed inter\u2010organellar communication is increasingly recognized to contribute to disease. In patient dopaminergic neurons harboring GBA1 mutations, TBC1D15 levels are decreased thereby increasing the duration of lyso\u2010mito MCSs and leading to mitochondrial dysfunction; this could be rescued by overexpression of TBC1D15. [ 170 ] Interestingly, PD\u2010linked mutations in PINK1 have been shown to also affect lyso\u2010mito MCS. [ 171 ] A similar lysosome\u2010centered pathology spreading to mitochondria through contact sites was suggested in a PLD3 model of late\u2010onset AD. [ 92 ] PLD3 is a lysosomal exonuclease degrading mtDNA delivered through mitophagy. Besides major lysosomal dysfunction and increased mitophagy, PLD3 deficiency as well as LOAD\u2010linked single nucleotide polymorphisms decreased the number of lyso\u2010mito MCSs, as well as the duration and size. [ 92 ] While lysosomal dysfunction caused by disease\u2010associated risk genes in general impacts downstream mitochondrial functions through affecting inter\u2010organellar communication, some of these are truly found in MCSs. This is for instance the case for the vacuolar protein sorting protein 13 (VPS13) family, VPS13A to D, which all function in bulk transport of glycerophospholipids between organelles. [ 172 , 173 , 174 ] Interestingly, each isoform is implicated in a distinct neurological disorder, underscoring their critical role in neuronal homeostasis. Moreover, they are also demonstrated to function in multiple MCS at once. For instance, VPS13A, being hit in choreo acanthocytosis, [ 175 , 176 ] localizes to ER\u2010LDs, ER\u2010mito and more recently ER\u2010plasma membrane MCSs. [ 173 , 177 ] On the other hand, VPS13C localizes to ER\u2010LD and ER\u2010Le/Lys MCSs. [ 173 ] Intriguingly, mutations in VPS13C are linked to rare early onset PD as well as dementia with Lewy Bodies, [ 178 ] providing a basis for common molecular mechanisms in distinct brain regions/neuronal populations linked to different Lewy Body diseases. While VPS13C is not associated with mitochondria, mutant VPS13C causes mitochondrial dyshomeostasis in cellular models, assuming indirect effects caused by lysosomal dysfunction linked to lipid transfer problems. [ 178 ] Moreover VPS13C deficiency was found to lead to mitochondrial leakiness that activated the cytosolic STING pathway. [ 149 ] Related to AD, causal gene products like APP and presenilin1 (PSEN1) and \u22122 (PSEN2) have been suggested to function in ER\u2010mitochondrial MCSs, explaining mitochondrial dysfunction as an early pathological feature. For instance, few groups localized PSENs and in particular PSEN2 in mito\u2010ER MCSs. [ 179 ] It was recently shown that palmitoylated APP (palAPP) partitions to lipid rafts, markedly in mitochondria\u2010ER MCSs. [ 180 ] Downregulation of these MCSs, either through RNA silencing or drugs targeting the sigma1 receptor (S1R), results in reduced \u03b2\u2010secretase cleavage of palAPP. As such, the upregulation of these contacts promoted trafficking of palAPP to the cell surface, \u03b2\u2010secretase cleavage, and subsequent A\u03b2 generation in axons. [ 180 ] Despite, both APP and PSENs have their resident locations and functions in the secretory and endolysosomal routes, [ 181 ] raising doubt on their physical presence in mito\u2010ER MCS. Firstly, PSEN2/\u03b3\u2010secretase has been shown to be restricted to LE/Lys whereas APP proteolysis is essentially occurring at the cell surface and endosomes and lysosomes. [ 181 , 182 ] Moreover, in PSEN\u2010deficient cells and neurons, APP\u2010CTFs accumulate in ER\u2010lyso MCSs where they reduced lysosomal Ca 2+ refilling from the ER. [ 25 ] These data support the mounting evidence for APP\u2010CTF accretion being causal to the observed endolysosomal defects in both familial and sporadic AD. [ 107 , 183 , 184 ] Instead of being localized to mito\u2010ER MCSs, an alternative explanation is through the role these proteins play in endolysosomal homeostasis. For instance, PSEN1 and 2 have been implicated in lysosomal calcium homeostasis, [ 26 , 185 ] pH effects, [ 186 , 187 ] the cellular location of cholesterol and sphingomyelin species, [ 188 ] and are involved in lysosomal proteolysis and autophagosome clearance. [ 184 , 189 ] The lysosomal defects resulting from altered PSEN expression/function could therefore indirectly impact mitochondrial functions, including ER\u2010mitochondrial communications. 4 THERAPEUTIC APPROACHES TARGETING ORGANELLAR HOMEOSTASIS The genuine link of mitochondrial dysfunction with disease, including neurodegeneration has given rise to a burgeoning industry with over 20 global companies dedicated to longevity and mitochondria research. Ranging from early\u2010stage start\u2010ups to publicly traded entities on Nasdaq, [ 190 ] these enterprises explore diverse strategies like mitochondrial transplants, gene therapies, and small molecule medications. Of particular interest in recent years is the focus on developing therapeutic approaches that target mitophagy, [ 191 , 192 ] aiming to combat neurodegeneration by facilitating the removal of damaged mitochondria and restoring the health of impaired neuronal mitochondria. Numerous strategies have been investigated, including the use of proton ionophores such as CCCP, FCCP, and DNP, albeit with limitations due to their potential adverse effects on the entire mitochondrial population, risking cellular energy shortage and cell death. [ 193 ] The newly discovered mitochondrial protonophore uncoupler, BAM15, presents a promising alternative that has demonstrated neuroprotective effects. [ 194 ] Where the compound may vary, the positive effect of inducing mito/autophagy has been associated with increasing the capacity and fitness of the lysosomal system; that is, only expecting a positive effect in the earliest stages of neurodegenerative diseases. This has been reviewed for the mTor inhibitor Rapamycin and other mitophagy\u2010inducers used in AD. [ 195 ] In addition, for PD, it might be necessary to bypass the possible dysfunction in the PINK1/Parkin mitophagy pathway for which currently AUTACs (Autophagy\u2010targeting chimeras) are being developed, as reviewed in. [ 196 ] Indeed, the pursuit of novel therapeutic approaches targeting lysosomal dysfunction in neurodegenerative diseases has unveiled promising avenues for treatment. Among these strategies, pharmacological interventions aimed at bolstering the stability, trafficking, and activity of disease\u2010specific lysosomal proteins have garnered attention. One way is the use of acidic nanoparticles to re\u2010acidify lysosomes and, as such rescue their lysosomal activity and integrity. Such particles were shown to prevent \u03b1\u2010syn\u2010induced neurodegeneration and synucleinopathy in mice [ 197 ] and restored endolysosomal impairments in primary fibroblasts of Down syndrome (3x APP allele). [ 198 ] Their beneficial effect was also demonstrated in vitro in cell lines expressing EOPD\u2010linked ATP13A2 mutations. [ 120 ] Interestingly, a similar strategy applied in non\u2010alcoholic fatty liver disease models showed that restoring lysosomal function also enhanced mitochondrial health to normal levels. [ 199 ] Further, metformin, a drug from the biguanide group that is mainly used in the treatment of diabetes mellitus type 2, was found beneficial in the treatment of AD. [ 200 ] Ma and colleagues showed that the PEN2\u2010ATP6AP1 axis functions as the key target for low\u2010dose metformin administration, impacting the glucose\u2010sensing pathway to activate AMPK [ 200 ] ; producing similarly advantageous results as those produced by glucose deprivation or calorie restriction. The potential reason for the numerous benefits and minimal side effects of metformin is its activation of the lysosomal AMPK pathway, while keeping AMP/ADP levels unchanged. [ 200 ] The use of pharmacological chaperones like AT2101 (afegostat\u2010tartrate, isofagomine) presents an intriguing prospect in enhancing the function of the lysosomal hydrolase acid\u2010\u03b2\u2010glucosidase variants associated with PD. [ 201 ] The discovery that AT2101 not only augments the functionality of specific lysosomal enzymes but also exhibits a broader impact, reducing \u03b1\u2010synuclein immunoreactivity in nigral dopaminergic neurons, hints at a more generalized beneficial effect transcending beyond specific mutations. [ 201 ] This finding is underscored by an initial clinical trial demonstrating improved scores on the Parkinson Disease Rating Scale, not restricted to patients with GBA1 mutations. [ 202 ] Moreover, the emergence of compounds like LTI\u2010291, a glucocerebrosidase activator, and Venglustat, a glucosylceramide synthase inhibitor, in initial clinical trial phases reflects the growing interest in targeting lysosomal pathways for therapeutic intervention. [ 203 ] These endeavors signify a promising shift in the treatment landscape for neurodegenerative diseases by addressing lysosomal dysfunction at a molecular level. With mutations in the TRPML1 gene, MCOLN1 , linked to mucolipidosis type IV, with TRPML1\u2010mediated Ca 2+ release to be reduced in other lysosomal storage disorders, including Niemann\u2010Pick disease type C, and with the channel's activity to be linked to autophagic clearance of A\u03b2 and tau in AD, different screens are being performed to identify specific agonists as well. [ 204 ] Different small chemical TRMPL1 agonists, such as MLSA1, SF\u201022 and MK6\u201083, have been synthesized and employed successfully in preclinical tests. [ 205 ] Even more, in 2019, Merck acquired Calporta Therapeutics, the small molecule therapeutics company who discovered ML\u2010SA1; providing a significant boost to exploiting TRPML1 as a therapeutic target for lysosomal storage disorders. Lastly, enzyme replacement therapy (ERT) stands out as another approach showing potential in combating neurodegenerative conditions by introducing functional lysosomal enzymes into affected cells, aiming to restore lysosomal hypertrophy, storage accumulation, and impaired autophagic flux. Notably, proof\u2010of\u2010principle studies utilizing direct delivery of recombinant cathepsin D have yielded promising results. [ 206 , 207 ] However, a significant impediment hindering the efficacy of ERT lies in the blood\u2010brain barrier's restrictive nature, which limits the transport of enzymes to the brain. Despite the remarkable progress made in lysosomal therapies, challenges persist. The translational success of these approaches from preclinical models to clinical settings remains an area warranting attention. Addressing concerns regarding blood\u2010brain barrier penetration, long\u2010term safety profiles, and the precise mechanisms governing lysosomal modulation is imperative for the advancement of these therapies into viable treatments for neurodegenerative diseases. CONFLICT OF INTEREST STATEMENT The authors have no conflict of interest to declare. ACKNOWLEDGMENTS The work in the Annaert lab is financially supported through VIB, KU Leuven (C14/21/095 and SMINF KA/20/085), the Research Foundation \u2013 Flanders (FWO; G0C3620N, G0C4220N and I001322N), SAO\u2010FRA (#2020/030 and 2022/022 to WA; 2023/034 to ZPVA) and the Alzheimer Association (AARF\u201020\u2010677499 to ZPVA). TL is a recipient of an FWO doctoral fellowship (11K1122N) and ZPVA of an FWO postdoctoral fellowship (1250425N). Illustrations were created with Biorender. DATA AVAILABILITY STATEMENT Data sharing is not applicable to this article as no new data were created or analyzed in this study. REFERENCES 1 Van Acker , Z. P. , Luyckx , E. , & Dewilde , S. ( 2018 ). Neuroglobin expression in the brain: A story of tissue homeostasis preservation . Molecular Neurobiology , 56 , 2101 \u2013 2122 . 29992530 2 Valenti , D. , & Vacca , R. A. ( 2022 ). Primary and secondary mitochondrial diseases: Etiologies and therapeutic strategies . Journal of Clinical Medicine , 11 , 4209 . 35887983 3 Rinaldi , A. ( 2023 ). The fountain of youth of mitochondrial research: Research is targeting mitochondrial dysfunction to tackle aging and much more, but hype is an increasing concern . Embo Reports , 24 , e58118 . 37768688 4 Peric , A. , & Annaert , W. ( 2015 ). Early etiology of Alzheimer's disease: Tipping the balance toward autophagy or endosomal dysfunction? Acta Neuropathologica , 129 , 363 \u2013 381 . 10.1007/s00401-014-1379-7 25556159 5 Rizzollo , F. , More , S. , Vangheluwe , P. , & Agostinis , P. ( 2021 ). The lysosome as a master regulator of iron metabolism . Trends in Biochemical Sciences , 46 , 960 \u2013 975 . 34384657 6 Mishra , S. , Jayadev , S. , & Young , J. E. ( 2024 ). Differential effects of SORL1 deficiency on the endo\u2010lysosomal network in human neurons and microglia . Philosophical transactions of the Royal Society of London. Series B, Biological sciences , 379 , 20220389 . 38368935 7 Macaskill , A. F. , Rinholm , J. E. , Twelvetrees , A. E. , Arancibia\u2010Carcamo , I. L. , Muir , J. , Fransson , A. , Aspenstrom , P. , Attwell , D. , & Kittler , J. T. ( 2009 ). Miro1 is a calcium sensor for glutamate receptor\u2010dependent localization of mitochondria at synapses . Neuron , 61 , 541 \u2013 555 . 19249275 8 Rangaraju , V. , Lauterbach , M. , & Schuman , E. M. ( 2019 ). Spatially stable mitochondrial compartments fuel local translation during plasticity . Cell , 176 , 73 \u2013 84.e15 . 30612742 9 Gross , N. J. , Getz , G. S. , & Rabinowitz , M. ( 1969 ). Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat . JBC , 244 , 1552 \u2013 1562 . 10 Goldsmith , J. , & Holzbaur , E. L. F. ( 2022 ). Proteomic profiling shows mitochondrial nucleoids are autophagy cargo in neurons: Implications for neuron maintenance and neurodegenerative disease . Autophagy , 18 , 2003 \u2013 2005 . 35343362 11 Goldsmith , J. , Ordureau , A. , Harper , J. W. , & Holzbaur , E. L. F. ( 2022 ). Holzbaur ELF. Brain\u2010derived autophagosome profiling reveals the engulfment of nucleoid\u2010enriched mitochondrial fragments by basal autophagy in neurons . Neuron , 110 , 967 \u2013 976.e8 . 35051374 12 Hill , S. E. , & Col\u00f3n\u2010Ramos , D. A. ( 2020 ). The journey of the synaptic autophagosome: A cell biological perspective . Neuron , 105 , 961 \u2013 973 . 32191859 13 Vogado Cunha Sr , C. A. , Burrinha , T. , & Almeida , C. G. ( 2022 ). Lysosomal subcellular distribution in neurons: Are there synaptic lysosomes? Alzheimer's & Dementia , 17 , e053844 . 14 Liv , N. , Fermie , J. , Ten Brink , C. B. M. , de Heus , C. , & Klumperman , J. ( 2023 ). Functional characterization of endo\u2010lysosomal compartments by correlative live\u2010cell and volume electron microscopy . Methods in Cell Biology , 177 , 301 \u2013 326 . 37451771 15 van der Beek , J. , de Heus , C. , Liv , N. , & Klumperman , J. ( 2022 ). Quantitative correlative microscopy reveals the ultrastructural distribution of endogenous endosomal proteins . Journal of Cell Biology , 221 , e202106044 . 34817533 16 Cason , S. E. , Mogre , S. S. , Holzbaur , E. L. F. , & Koslover , E. F. ( 2022 ). Spatiotemporal analysis of axonal autophagosome\u2010lysosome dynamics reveals limited fusion events and slow maturation . Molecular Biology of the Cell , 33 , ar123 . 36044338 17 Cataldo , A. M. , Peterhoff , C. M. , Troncoso , J. C. , Gomez\u2010Isla , T. , Hyman , B. T. , & Nixon , R. A. ( 2000 ). Endocytic pathway abnormalities precede amyloid \u03b2 deposition in sporadic Alzheimer's disease and down syndrome . American Journal of Pathology , 157 , 277 \u2013 286 . 10880397 18 Rockenstein , E. , Schwach , G. , Ingolic , E. , Adame , A. , Crews , L. , Mante , M. , Pfragner , R. , Schreiner , E. , Windisch , M. , & Masliah , E. ( 2005 ). Lysosomal pathology associated with alpha\u2010synuclein accumulation in transgenic models using an eGFP fusion protein . Journal of Neuroscience Research , 80 , 247 \u2013 259 . 15765523 19 Davis , S. E. , Cook , A. K. , Hall , J. A. , Voskobiynyk , Y. , Carullo , N. V. , Boyle , N. R. , Hakim , A. R. , Anderson , K. M. , Hobdy , K. P. , Pugh , D. A. , Murchison , C. F. , Mcmeekin , L. J. , Simmons , M. , Margolies , K. A. , Cowell , R. M. , Nana , A. L. , Spina , S. , Grinberg , L. T. , Miller , B. L. , \u2026 Arrant , A. E. ( 2023 ). Patients with sporadic FTLD exhibit similar increases in lysosomal proteins and storage material as patients with FTD due to GRN mutations . Acta Neuropathologica Communications , 11 , 70 . 37118844 20 Drobny , A. , Boros , F. A. , Balta , D. , Prieto Huarcaya , S. , Caylioglu , D. , Qazi , N. , Vandrey , J. , Schneider , Y. , Dobert , J. P. , Pitcairn , C. , Mazzulli , J. R. , & Zunke , F. ( 2023 ). Reciprocal effects of alpha\u2010synuclein aggregation and lysosomal homeostasis in synucleinopathy models . Translational Neurodegeneration , 12 , 31 . 37312133 21 Murphy , K. E. , Gysbers , A. M. , Abbott , S. K. , Tayebi , N. , Kim , W. S. , Sidransky , E. , Cooper , A. , Garner , B. , & Halliday , G. M. ( 2014 ). Reduced glucocerebrosidase is associated with increased \u03b1\u2010synuclein in sporadic Parkinson's disease . Brain , 137 , 834 \u2013 848 . 24477431 22 Hattersley , K. J. , Carosi , J. M. , Hein , L. K. , Bensalem , J. , & Sargeant , T. J. ( 2021 ). PICALM regulates cathepsin D processing and lysosomal function . Biochemical and Biophysical Research Communications , 570 , 103 \u2013 109 . 34311200 23 Mustaly\u2010Kalimi , S. , Gallegos , W. , Marr , R. A. , Gilman\u2010Sachs , A. , Peterson , D. A. , Sekler , I. , & Stutzmann , G. E. ( 2022 ). Protein mishandling and impaired lysosomal proteolysis generated through calcium dysregulation in Alzheimer's disease . Philosophical transactions of the Royal Society of London. Series B, Biological sciences , 119 , e2211999119 . 24 Lee , J.\u2010H. , Mcbrayer , M. K. , Wolfe , D. M. , Haslett , L. J. , Kumar , A. , Sato , Y. , Lie , P. P. Y. , Mohan , P. , Coffey , E. E. , Kompella , U. , Mitchell , C. H. , Lloyd\u2010Evans , E. , & Nixon , R. A. ( 2015 ). Presenilin 1 maintains lysosomal Ca(2+) homeostasis via TRPML1 by regulating vATPase\u2010mediated lysosome acidification . Cell Reports , 12 , 1430 \u2013 1444 . 10.1016/j.celrep.2015.07.050 26299959 25 Bretou , M. , Sannerud , R. , Escamilla\u2010Ayala , A. , Leroy , T. , Vrancx , C. , Van Acker , Z. P. , Perdok , A. , Vermeire , W. , Vorsters , I. , Van Keymolen , S. , Maxson , M. , Pavie , B. , Wierda , K. , Eskelinen , E.\u2010L. , & Annaert , W. ( 2024 ). Accumulation of APP C\u2010terminal fragments causes endolysosomal dysfunction through the dysregulation of late endosome to lysosome\u2010ER contact sites . Developmental Cell , 59 , 1571 \u2013 1592.e9 . 38626765 26 Coen , K. , Flannagan , R. S. , Baron , S. , Carraro\u2010Lacroix , L. R. , Wang , D. , Vermeire , W. , Michiels , C. , Munck , S. , Baert , V. , Sugita , S. , Wuytack , F. , Hiesinger , P. R. , Grinstein , S. , & Annaert , W. ( 2012 ). Lysosomal calcium homeostasis defects, not proton pump defects, cause endo\u2010lysosomal dysfunction in PSEN\u2010deficient cells . Journal of Cell Biology , 198 , 23 \u2013 35 . 10.1083/jcb.201201076 22753898 27 Barbero\u2010Camps , E. , Roca\u2010Agujetas , V. , Bartolessis , I. , De Dios , C. , Fern\u00e1ndez\u2010Checa , J. C. , Mar\u00ed , M. , Morales , A. , Hartmann , T. , & Colell , A. ( 2018 ). Cholesterol impairs autophagy\u2010mediated clearance of amyloid beta while promoting its secretion . Autophagy , 14 , 1129 \u2013 1154 . 29862881 28 Roca\u2010Agujetas , V. , Barbero\u2010Camps , E. , De Dios , C. , Podlesniy , P. , Abadin , X. , Morales , A. , Mar\u00ed , M. , Trull\u00e0s , R. , & Colell , A. ( 2021 ). Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer's disease . Molecular Neurodegeneration , 16 , 15 . 33685483 29 Vrijsen , S. , Vrancx , C. , Del Vecchio , M. , Swinnen , J. V. , Agostinis , P. , Winderickx , J. , Vangheluwe , P. , & Annaert , W. ( 2022 ). Inter\u2010organellar communication in Parkinson's and Alzheimer's disease: Looking beyond endoplasmic reticulum\u2010mitochondria contact sites . Frontiers in neuroscience , 16 , 900338 . 35801175 30 Wilson , E. L. , & Metzakopian , E. ( 2021 ). ER\u2010mitochondria contact sites in neurodegeneration: Genetic screening approaches to investigate novel disease mechanisms . Cell Death and Differentiation , 28 , 1804 \u2013 1821 . 33335290 31 Moreira , J. D. , Gopal , D. M. , Kotton , D. N. , & Fetterman , J. L. ( 2021 ). Gaining insight into mitochondrial genetic variation and downstream pathophysiology: What can i(PSCs) Do . Genes (Basel) , 12 , 1668 . 34828274 32 Mullin , N. K. , Voigt , A. P. , Flamme\u2010Wiese , M. J. , Liu , X. , Riker , M. J. , Varzavand , K. , Stone , E. M. , Tucker , B. A. , & Mullins , R. F. ( 2023 ). Multimodal single\u2010cell analysis of nonrandom heteroplasmy distribution in human retinal mitochondrial disease . JCI Insight , 8 , e165937 . 37289546 33 Maruszak , A. , Canter , J. A. , Styczy\u0144ska , M. , \u017bekanowski , C. , & Barcikowska , M. ( 2009 ). Mitochondrial haplogroup H and Alzheimer's disease\u2013is there a connection? Neurobiology of Aging , 30 , 1749 \u2013 1755 . 18308428 34 Maruszak , A. , Safranow , K. , Branicki , W. , Gaw\u0119da\u2010Walerych , K. , Po\u015bpiech , E. , Gabryelewicz , T. , Canter , J. A. , Barcikowska , M. , & \u017bekanowski , C. ( 2011 ). The impact of mitochondrial and nuclear DNA variants on late\u2010onset Alzheimer's disease risk . Journal of Alzheimer's Disease , 27 , 197 \u2013 210 . 35 Watts , A. , Chalise , P. , Hu , J. , Hui , D. , Pa , J. , Andrews , S. J. , Michaelis , E. K. , & Swerdlow , R. H. ( 2022 ). A mitochondrial DNA haplogroup defines patterns of five\u2010year cognitive change . Journal of Alzheimer's Disease , 89 , 913 \u2013 922 . 36 Coskun , P. , Beal , M. , & Wallace , D. ( 2004 ). Alzheimer's brains harbor somatic mtDNA control\u2010region mutations that suppress mitochondrial transcription and replication . Proceedings of the National Academy of Sciences of the United States of America , 101 , 10726 \u2013 10731 . 15247418 37 Picca , A. , Calvani , R. , Coelho\u2010Junior , H. J. , Landi , F. , Bernabei , R. , & Marzetti , E. ( 2020 ). Mitochondrial dysfunction, oxidative stress, and neuroinflammation: Intertwined roads to neurodegeneration . ANTIOXIDANTS , 9 , 647 . 32707949 38 Alvarez , V. , Corao , A. I. , Alonso\u2010Montes , C. , S\u00e1nchez\u2010Ferrero , E. , De Mena , L. , Morales , B. , Garc\u00eda\u2010Castro , M. , & Coto , E. ( 2008 ). Mitochondrial transcription factor A (TFAM) gene variation and risk of late\u2010onset Alzheimer's disease . Journal of Alzheimer's Disease , 13 , 275 \u2013 280 . 39 Nido , G. S. , D\u00f6lle , C. , Fl\u00f8nes , I. , Tuppen , H. A. , Alves , G. , Tysnes , O.\u2010B. , Haugarvoll , K. , & Tzoulis , C. ( 2018 ). Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease . Neurobiology of Aging , 63 , 120 \u2013 127 . 29257976 40 Bender , A. , Krishnan , K. J. , Morris , C. M. , Taylor , G. A. , Reeve , A. K. , Perry , R. H. , Jaros , E. , Hersheson , J. S. , Betts , J. , Klopstock , T. , Taylor , R. W. , & Turnbull , D. M. ( 2006 ). High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease . Nature Genetics , 38 , 515 \u2013 517 . 16604074 41 Gu , G. , Reyes , P. F. , Golden , G. T. , Woltjer , R. L. , Hulette , C. , Montine , T. J. , & Zhang , J. ( 2002 ). Mitochondrial DNA deletions/rearrangements in Parkinson disease and related neurodegenerative disorders . Journal of Neuropathology and Experimental Neurology , 61 , 634 \u2013 639 . 12125742 42 Ross , O. , McCormack , R. , Maxwell , L. D. , Duguid , R. A. , Quinn , D. J. , Barnett , Y. A. , Rea , I. M. , El\u2010Agnaf , O. M. , Gibson , J. M. , Wallace , A. , Middleton , D. , & Curran , M. D. ( 2003 ). mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish . Experimental Gerontology , 38 , 397 \u2013 405 . 12670626 43 Smigrodzki , R. , Parks , J. , & Parker , W. D. ( 2004 ). High frequency of mitochondrial complex I mutations in Parkinson's disease and aging . Neurobiology of Aging , 25 , 1273 \u2013 1281 . 15465623 44 Lin , C.\u2010H. , Tsai , P.\u2010I. , Lin , H.\u2010Y. , Hattori , N. , Funayama , M. , Jeon , B. , Sato , K. , Abe , K. , Mukai , Y. , Takahashi , Y. , Li , Y. , Nishioka , K. , Yoshino , H. , Daida , K. , Chen , M.\u2010L. , Cheng , J. , Huang , C.\u2010Y. , Tzeng , S.\u2010R. , Wu , Y.\u2010S. , \u2026 Wu , R.\u2010M. ( 2021 ). Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy . Brain , 143 , 3352 \u2013 3373 . 45 Hudson , G. , Nalls , M. , Evans , J. R. , Breen , D. P. , Winder\u2010Rhodes , S. , Morrison , K. E. , Morris , H. R. , Williams\u2010Gray , C. H. , Barker , R. A. , Singleton , A. B. , Hardy , J. , Wood , N. E. , Burn , D. J. , & Chinnery , P. F. ( 2013 ). Two\u2010stage association study and meta\u2010analysis of mitochondrial DNA variants in Parkinson disease . Neurology , 80 , 2042 \u2013 2048 . 23645593 46 Nakabeppu , Y. , Tsuchimoto , D. , Yamaguchi , H. , & Sakumi , K. ( 2007 ). Oxidative damage in nucleic acids and Parkinson's disease . Journal of Neuroscience Research , 85 , 919 \u2013 934 . 17279544 47 Fukae , J. , Takanashi , M. , Kubo , S.\u2010I. , Nishioka , K.\u2010I. , Nakabeppu , Y. , Mori , H. , Mizuno , Y. , & Hattori , N. ( 2005 ). Expression of 8\u2010oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders . Acta Neuropathologica , 109 , 256 \u2013 262 . 15841414 48 Ingram , C. J. E. , Weale , M. E. , Plaster , C. A. , Morrison , K. E. , Goodall , E. F. , Pall , H. S. , Beck , M. , Jablonka , S. , Sendtner , M. , Fisher , E. M. C. , Bradman , N. , & Kasperavi\u010di\u016bt\u0117 , D. ( 2012 ). Analysis of European case\u2010control studies suggests that common inherited variation in mitochondrial DNA is not involved in susceptibility to amyotrophic lateral sclerosis . Amyotrophic Lateral Sclerosis , 13 , 341 \u2013 346 . 22409358 49 Rose , G. , Longo , T. , Maletta , R. , Passarino , G. , Bruni , A. C. , & De Benedictis , G. ( 2008 ). No evidence of association between frontotemporal dementia and major European mtDNA haplogroups . European Journal of Neurology , 15 , 1006 \u2013 1008 . 18637035 50 Brockmann , S. J. , Buck , E. , Casoli , T. , Meirelles , J. L. , Ruf , W. P. , Fabbietti , P. , Holzmann , K. , Weishaupt , J. H. , Ludolph , A. C. , Conti , F. , & Danzer , K. M. ( 2023 ). Mitochondrial genome study in blood of maternally inherited ALS cases . Human Genomics , 17 , 1 \u2013 13 . 36597107 51 Amore , G. , Vacchiano , V. , La Morgia , C. , Valentino , M. L. , Caporali , L. , Fiorini , C. , Ormanbekova , D. , Salvi , F. , Bartoletti\u2010Stella , A. , Capellari , S. , Liguori , R. , & Carelli , V. ( 2023 ). Co\u2010occurrence of amyotrophic lateral sclerosis and Leber's hereditary optic neuropathy: Is mitochondrial dysfunction a modifier? Journal of Neurology , 270 , 559 \u2013 564 . 36066624 52 Dhaliwal , G. K. , & Grewal , R. P. ( 2000 ). Mitochondrial DNA deletion mutation levels are elevated in ALS brains . Neuroreport , 11 , 2507 \u2013 2509 . 10943712 53 Grazina , M. , Silva , F. , Santana , I. , Santiago , B. , Mendes , C. , Sim\u00f5es , M. , Oliveira , M. , Cunha , L. , & Oliveira , C. ( 2004 ). Frontotemporal dementia and mitochondrial DNA transitions . Neurobiology of Disease , 15 , 306 \u2013 311 . 15006700 54 Nie , Y. , Murley , A. , Golder , Z. , Rowe , J. B. , Allinson , K. , & Chinnery , P. F. ( 2022 ). Heteroplasmic mitochondrial DNA mutations in frontotemporal lobar degeneration . Acta Neuropathologica , 143 , 687 \u2013 695 . 35488929 55 Salvany , S. , Casanovas , A. , Piedrafita , L. , Gras , S. , Calder\u00f3 , J. , & Esquerda , J. E. ( 2022 ). Accumulation of misfolded SOD1 outlines distinct patterns of motor neuron pathology and death during disease progression in a SOD1G93A mouse model of amyotrophic lateral sclerosis . Brain Pathology , 32 , e13078 . 35584812 56 Van Acker , Z. P. , Declerck , K. , Luyckx , E. , Vanden Berghe , W. , & Dewilde , S. ( 2019 ). Non\u2010methylation\u2010linked mechanism of rest\u2010induced neuroglobin expression impacts mitochondrial phenotypes in a mouse model of amyotrophic lateral sclerosis . Neuroscience , 412 , 233 \u2013 247 . 31158439 57 Ferri , A. , Fiorenzo , P. , Nencini , M. , Cozzolino , M. , Pesaresi , M. G. , Valle , C. , Sepe , S. , Moreno , S. , & Carr\u00ec , M. T. ( 2010 ). Glutaredoxin 2 prevents aggregation of mutant SOD1 in mitochondria and abolishes its toxicity . Human Molecular Genetics , 19 , 4529 \u2013 4542 . 20829229 58 Pedrini , S. , Sau , D. , Guareschi , S. , Bogush , M. , Brown , Jr R. H. , Naniche , N. , Kia , A. , Trotti , D. , & Pasinelli , P. ( 2010 ). ALS\u2010linked mutant SOD1 damages mitochondria by promoting conformational changes in Bcl\u20102 . Human Molecular Genetics , 19 , 2974 \u2013 2986 . 20460269 59 Abeliovich , H. , Debnath , J. , Ding , W.\u2010X. , Jackson , W. T. , Kim , D.\u2010H. , Klionsky , D. J. , Ktistakis , N. , Margeta , M. , M\u00fcnz , C. , Petersen , M. , Sadoshima , J. , & Vergne , I. ( 2023 ). Where is the field of autophagy research heading? Autophagy , 19 , 1049 \u2013 1054 . 36628432 60 Kim , M. , Sandford , E. , Gatica , D. , Qiu , Y. , Liu , X. , Zheng , Y. , Schulman , B. A. , Xu , J. , Semple , I. , Ro , S.\u2010H. , Kim , B. , Mavioglu , R. N. , Tolun , A. , Jipa , A. , Takats , S. , Karpati , M. , Li , J. Z. , Yapici , Z. , Juhasz , G. , \u2026, Burmeister , M. ( 2016 ). Mutation in ATG5 reduces autophagy and leads to ataxia with developmental delay . Elife , 5 , e12245 . 26812546 61 Jelani , M. , Dooley , H. C. , Gubas , A. , Mohamoud , H. S. A. , Khan , M. T. M. , Ali , Z. , Kang , C. , Rahim , F. , Jan , A. , Vadgama , N. , Khan , M. I. , Al\u2010Aama , J. Y. , Khan , A. , Tooze , S. A. , & Nasir , J. ( 2019 ). A mutation in the major autophagy gene, WIPI2, associated with global developmental abnormalities . Brain , 142 , 1242 \u2013 1254 . 30968111 62 Suleiman , J. , Allingham\u2010Hawkins , D. , Hashem , M. , Shamseldin , H. E. , Alkuraya , F. S. , & El\u2010Hattab , A. W. ( 2018 ). WDR45B\u2010related intellectual disability, spastic quadriplegia, epilepsy, and cerebral hypoplasia: A consistent neurodevelopmental syndrome . Clinical Genetics , 93 , 360 \u2013 364 . 28503735 63 Haack , T. B. , Hogarth , P. , Kruer , M. C. , Gregory , A. , Wieland , T. , Schwarzmayr , T. , Graf , E. , Sanford , L. , Meyer , E. , Kara , E. , Cuno , S. M. , Harik , S. I. , Dandu , V. H. , Nardocci , N. , Zorzi , G. , Dunaway , T. , Tarnopolsky , M. , Skinner , S. , Frucht , S. , \u2026 Hayflick , S. J. ( 2012 ). Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X\u2010linked dominant form of NBIA . American Journal of Human Genetics , 91 , 1144 \u2013 1149 . 23176820 64 Cullup , T. , Kho , A. L. , Dionisi\u2010Vici , C. , Brandmeier , B. , Smith , F. , Urry , Z. , Simpson , M. A. , Yau , S. , Bertini , E. , Mcclelland , V. , Al\u2010Owain , M. , Koelker , S. , Koerner , C. , Hoffmann , G. F. , Wijburg , F. A. , Hoedt , A. E. T. , Rogers , R. C. , Manchester , D. , Miyata , R. , \u2026 Jungbluth , H. ( 2013 ). Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy . Nature Genetics , 45 , 83 \u2013 87 . 23222957 65 Pottier , C. , Bieniek , K. F. , Finch , N. , Van De Vorst , M. , Baker , M. , Perkersen , R. , Brown , P. , Ravenscroft , T. , Van Blitterswijk , M. , Nicholson , A. M. , Deture , M. , Knopman , D. S. , Josephs , K. A. , Parisi , J. E. , Petersen , R. C. , Boylan , K. B. , Boeve , B. F. , Graff\u2010Radford , N. R. , Veltman , J. A. , \u2026 Rademakers , R. ( 2015 ). Whole\u2010genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease . Acta Neuropathologica , 130 , 77 \u2013 92 . 25943890 66 Quinn , P. M. J. , Moreira , P. I. , Ambr\u00f3sio , A. F. , & Alves , C. H. ( 2020 ). PINK1 /PARKIN signalling in neurodegeneration and neuroinflammation . Acta Neuropathol Commun , 8 , 1 \u2013 20 . 31915069 67 Liu , T. , Wetzel , L. , Zhu , Z. , Kumaraguru , P. , Gorthi , V. , Yan , Y. , Bukhari , M. Z. , Ermekbaeva , A. , Jeon , H. , Kee , T. R. , Woo , J.\u2010A. A. , & Kang , D. E. ( 2023 ). Disruption of Mitophagy Flux through the PARL\u2010PINK1 Pathway by CHCHD10 Mutations or CHCHD10 Depletion . Cells , 12 , 2781 . 38132101 68 Shao , W. , Todd , T. W. , Wu , Y. , Jones , C. Y. , Tong , J. , Jansen\u2010West , K. , Daughrity , L. M. , Park , J. , Koike , Y. , Kurti , A. , Yue , M. , Castanedes\u2010Casey , M. , Del Rosso , G. , Dunmore , J. A. , Zanetti Alepuz , D. , Oskarsson , B. , Dickson , D. W. , Cook , C. N. , Prudencio , M. , \u2026 Petrucelli , L. ( 2023 ). Two FTD\u2010ALS genes converge on the endosomal pathway to induce TDP\u201043 pathology and degeneration . Science , 378 , 94 \u2013 9 . 69 Burchell , V. S. , Nelson , D. E. , Sanchez\u2010Martinez , A. , Delgado\u2010Camprubi , M. , Ivatt , R. M. , Pogson , J. H. , Randle , S. J. , Wray , S. , Lewis , P. A. , Houlden , H. , Abramov , A. Y. , Hardy , J. , Wood , N. W. , Whitworth , A. J. , Laman , H. , & Plun\u2010Favreau , H. ( 2013 ). The Parkinson's disease\u2010linked proteins Fbxo7 and Parkin interact to mediate mitophagy . Nature Neuroscience , 16 , 1257 \u2013 1265 . 23933751 70 Kraus , F. , Goodall , E. A. , Smith , I. R. , Jiang , Y. , Paoli , J. C. , Adolf , F. , Zhang , J. , Paulo , J. A. , Schulman , B. A. , Harper , J. W. , Brice , A. , Guedin , D. , Gautier , C. A. , & Corti , O. ( 2023 ). The protein kinase PINK1 and the ubiquitin ligase Parkin promote mitochondrial clearance through a feed\u2010forward process involving ubiquitin (Ub) phosphorylation (pUb) . Embo Reports , 24 , e56399 . 37334901 71 Imberechts , D. , Kinnart , I. , Wauters , F. , Terbeek , J. , Manders , L. , Wierda , K. , Eggermont , K. , Madeiro , R. F. , Sue , C. , Verfaillie , C. , & Vandenberghe , W. ( 2022 ). DJ\u20101 is an essential downstream mediator in PINK1/parkin\u2010dependent mitophagy . Brain , awac313 . 72 Van Acker , Z. P. , Bretou , M. , & Annaert , W. ( 2019 ). Endo\u2010lysosomal dysregulations and late\u2010onset Alzheimer's disease: Impact of genetic risk factors . Molecular Neurodegeneration , 14 , 20 . 10.1186/s13024-019-0323-7 31159836 73 Peri\u00f1\u00e1n , M. T. , Mac\u00edas\u2010Garc\u00eda , D. , Labrador\u2010Espinosa , M. \u00c1. , Jes\u00fas , S. , Buiza\u2010Rueda , D. , Adarmes\u2010G\u00f3mez , A. D. , Mu\u00f1oz\u2010Delgado , L. , G\u00f3mez\u2010Garre , P. , & Mir , P. ( 2021 ). Association of PICALM with cognitive impairment in Parkinson's disease . Movement Disorders , 36 , 118 \u2013 123 . 32914893 74 Ando , K. , De Decker , R. , Vergara , C. , Yilmaz , Z. , Mansour , S. , Suain , V. , Sleegers , K. , De Fisenne , M.\u2010A. , Houben , S. , Potier , M.\u2010C. , Duyckaerts , C. , Watanabe , T. , Bu\u00e9e , L. , Leroy , K. , & Brion , J.\u2010P. ( 2020 ). Picalm reduction exacerbates tau pathology in a murine tauopathy model . Acta Neuropathologica , 139 , 773 \u2013 789 . 31925534 75 Moreau , K. , Fleming , A. , Imarisio , S. , Lopez Ramirez , A. , Mercer , J. L. , Jimenez\u2010Sanchez , M. , Bento , C. F. , Puri , C. , Zavodszky , E. , Siddiqi , F. , Lavau , C. P. , Betton , M. , O'kane , C. J. , Wechsler , D. S. , & Rubinsztein , D. C. ( 2014 ). PICALM modulates autophagy activity and tau accumulation . Nature Communications , 5 , 4998 . 10.1038/ncomms5998 76 Rothenberg , C. , Srinivasan , D. , Mah , L. , Kaushik , S. , Peterhoff , C. M. , Ugolino , J. , Fang , S. , Cuervo , A. M. , Nixon , R. A. , & Monteiro , M. J. ( 2010 ). Ubiquilin functions in autophagy and is degraded by chaperone\u2010mediated autophagy . Human Molecular Genetics , 19 , 3219 \u2013 3232 . 20529957 77 Yue , Z. , Wang , S. , Yan , W. , & Zhu , F. ( 2015 ). Association of UBQ\u20108i polymorphism with Alzheimer's disease in Caucasians: A meta\u2010analysis . International Journal of Neuroscience , 125 , 395 \u2013 401 . 25010605 78 Phung , T. H. , Tatman , M. , & Monteiro , M. J. ( 2023 ). UBQLN2 undergoes a reversible temperature\u2010induced conformational switch that regulates binding with HSPA1B: ALS/FTD mutations cripple the switch but do not destroy HSPA1B binding . Biochimica et Biophysica Acta. General Subjects , 1867 , 130284 . 36423739 79 Sandoval\u2010Pistorius , S. S. , Gerson , J. E. , Liggans , N. , Ryou , J. H. , Oak , K. , Li , X. , Negron\u2010Rios , K. Y. , Fischer , S. , Barsh , H. , Crowley , E. V. , Skinner , M. E. , Sharkey , L. M. , Barmada , S. J. , & Paulson , H. L. ( 2023 ). Ubiquilin\u20102 regulates pathological alpha\u2010synuclein . Scientific Reports , 13 , 293 . 36609661 80 Adegoke , O. O. , Qiao , F. , Liu , Y. , Longley , K. , Feng , S. , & Wang , H. ( 2017 ). Overexpression of ubiquilin\u20101 alleviates Alzheimer's disease\u2010caused cognitive and motor deficits and reduces amyloid\u2010\u03b2 accumulation in mice . Journal of Alzheimer's disease , 59 , 575 \u2013 590 . 81 Sannerud , R. , & Annaert , W. ( 2009 ). Trafficking, a key player in regulated intramembrane proteolysis . Seminars In Cell & Developmental Biology , 20 , 183 \u2013 190 . 19056506 82 Natunen , T. , Takalo , M. , Kemppainen , S. , Leskel\u00e4 , S. , Marttinen , M. , Kurkinen , K. M. A. , Pursiheimo , J.\u2010P. , Saraj\u00e4rvi , T. , Viswanathan , J. , Gabbouj , S. , Solje , E. , Tahvanainen , E. , Pirttim\u00e4ki , T. , Kurki , M. , Paananen , J. , Rauramaa , T. , Miettinen , P. , M\u00e4kinen , P. , Leinonen , V. , \u2026 Hiltunen , M. ( 2016 ). Relationship between ubiquilin\u20101 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell\u2010based models . Neurobiology of Disease , 85 , 187 \u2013 205 . 26563932 83 Whiteley , A. M. , Prado , M. A. , Peng , I. , Abbas , A. R. , Haley , B. , Paulo , J. A. , Reichelt , M. , Katakam , A. , Sagolla , M. , Modrusan , Z. , Lee , D. Y. , Roose\u2010Girma , M. , Kirkpatrick , D. S. , Mckenzie , B. S. , Gygi , S. P. , Finley , D. , & Brown , E. J. ( 2017 ). Ubiquilin1 promotes antigen\u2010receptor mediated proliferation by eliminating mislocalized mitochondrial proteins . Elife , 6 , e26435 . 28933694 84 Fern\u00e1ndez\u2010Mosquera , L. , Diogo , C. V. , Yambire , K. F. , Santos , G. L. , Luna S\u00e1nchez , M. , B\u00e9nit , P. , Rustin , P. , Lopez , L. C. , Milosevic , I. , & Raimundo , N. ( 2017 ). Acute and chronic mitochondrial respiratory chain deficiency differentially regulate lysosomal biogenesis . Scientific Reports , 7 , 45076 . 28345620 85 Demers\u2010Lamarche , J. , Guillebaud , G. , Tlili , M. , Todkar , K. , B\u00e9langer , N. , Grondin , M. , Nguyen , A. P. , Michel , J. , & Germain , M. ( 2016 ). Loss of mitochondrial function impairs lysosomes . JBC , 291 , 10263 \u2013 10276 . 86 Silva , D. , Esteves , A. , Oliveira , C. , & Cardoso , S. ( 2017 ). Mitochondrial metabolism power SIRT2\u2010dependent deficient traffic causing Alzheimer's\u2010disease related pathology . Molecular Neurobiology , 54 , 4021 \u2013 4040 . 27311773 87 Brewer , G. , Herrera , R. , Philipp , S. , Sosna , J. , Reyes\u2010Ruiz , J. , & Glabe , C. ( 2020 ). Age\u2010related intraneuronal aggregation of amyloid\u2010\u03b2 in endosomes, mitochondria, autophagosomes, and lysosomes . Journal of Alzheimer's disease , 73 , 229 \u2013 246 . 88 Weidling , I. W. , Wilkins , H. M. , Koppel , S. J. , Hutfles , L. , Wang , X. , Kalani , A. , Menta , B. W. , Ryan , B. , Perez\u2010Ortiz , J. , Gamblin , T. C. , & Swerdlow , R. H. ( 2020 ). Mitochondrial DNA manipulations affect tau oligomerization . Journal of Alzheimer's disease , 77 , 149 \u2013 163 . 89 Clark , E. H. , V\u00e1zquez de la Torre , A. , Hoshikawa , T. , & Briston , T. ( 2021 ). Targeting mitophagy in Parkinson's disease . JBC , 296 , 100209 . 90 Van Acker , Z. P. , Perdok , A. , Bretou , M. , & Annaert , W. ( 2021 ). The microglial lysosomal system in Alzheimer's disease: guardian against proteinopathy . Ageing Research Reviews , 71 , 101444 . 34391945 91 Perdig\u00e3o , C. , Barata , M. A. , Ara\u00fajo , M. N. , Mirfakhar , F. S. , Castanheira , J. , & Guimas Almeida , C. ( 2020 ). Intracellular trafficking mechanisms of synaptic dysfunction in Alzheimer's disease . Frontiers in Cellular Neuroscience , 14 , 72 . 32362813 92 Van Acker , Z. P. , Perdok , A. , Hellemans , R. , North , K. , Vorsters , I. , Cappel , C. , Dehairs , J. , Swinnen , J. V. , Sannerud , R. , Bretou , M. , Damme , M. , & Annaert , W. ( 2023 ). PLD3 degrades mitochondrial DNA to keep nucleotide signaling and APP metabolism in check . Nature Communications , 14 , 2847 . 93 Fote , G. M. , Geller , N. R. , Efstathiou , N. E. , Hendricks , N. , Vavvas , D. G. , Reidling , J. C. , Thompson , L. M. , & Steffan , J. S. ( 2022 ). Isoform\u2010dependent lysosomal degradation and internalization of apolipoprotein E requires autophagy proteins . Journal of Cell Science , 135 , jcs258687 . 34982109 94 Costa\u2010Laparra , I. , Juarez\u2010Escoto , E. , Vicario , C. , Moratalla , R. , & Garcia\u2010Sanz , P. ( 2023 ). APOE & epsilon;4 allele, along with G206D\u2010PSEN1 mutation, alters mitochondrial networks and their degradation in Alzheimer's disease . Frontiers in Aging Neuroscience , 15 , 1087072 . 37455931 95 Tambini , M. D. , Pera , M. , Kanter , E. , Yang , H. , Guardia\u2010Laguarta , C. , Holtzman , D. , Sulzer , D. , Area\u2010Gomez , E. , & Schon , E. A. ( 2016 ). ApoE4 upregulates the activity of mitochondria\u2010associated ER membranes . Embo Reports , 17 , 27 \u2013 36 . 26564908 96 Wahrle , S. E. , Jiang , H. , Parsadanian , M. , Legleiter , J. , Han , X. , Fryer , J. D. , Kowalewski , T. , & Holtzman , D. M. ( 2004 ). ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte\u2010secreted apoE . JBC , 279 , 40987 \u2013 40993 . 97 Zhao , J. , Davis , M. D. , Martens , Y. A. , Shinohara , M. , Graff\u2010Radford , N. R. , Younkin , S. G. , Wszolek , Z. K. , Kanekiyo , T. , & Bu , G. ( 2017 ). APOE \u03b54/\u03b54 diminishes neurotrophic function of human iPSC\u2010derived astrocytes . Human Molecular Genetics , 26 , 2690 \u2013 2700 . 28444230 98 Lefterov , I. , Fitz , N. F. , Cronican , A. , Lefterov , P. , Staufenbiel , M. , & Koldamova , R. ( 2009 ). Memory deficits in APP23/Abca1\u00b1 mice correlate with the level of A\u03b2 oligomers . ASN Neuro , 1 , AN20090015 . 99 Yang , J. , Kou , J. , Lalonde , R. , & Fukuchi , K.\u2010I. ( 2017 ). Intracranial IL\u201017A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease . Brain, Behavior, and Immunity , 65 , 262 \u2013 273 . 28526436 100 Fitz , N. F. , Cronican , A. A. , Saleem , M. , Fauq , A. H. , Chapman , R. , Lefterov , I. , & Koldamova , R. ( 2012 ). Abca1 deficiency affects Alzheimer's disease\u2010like phenotype in human ApoE4 but not in ApoE3\u2010targeted replacement mice . Journal of Neuroscience , 32 , 13125 \u2013 13136 . 22993429 101 Moskal , N. , Visanji , N. P. , Gorbenko , O. , Narasimhan , V. , Tyrrell , H. , Nash , J. , Lewis , P. N. , & Mcquibban , G. A. ( 2023 ). An AI\u2010guided screen identifies probucol as an enhancer of mitophagy through modulation of lipid droplets . Plos Biology , 21 , e3001977 . 36862640 102 Real , R. , Martinez\u2010Carrasco , A. , Reynolds , R. H. , Lawton , M. A. , Tan , M. M. X. , Shoai , M. , Corvol , J.\u2010C. , Ryten , M. , Bresner , C. , Hubbard , L. , Brice , A. , Lesage , S. , Faouzi , J. , Elbaz , A. , Artaud , F. , Williams , N. , Hu , M. T. M. , Ben\u2010Shlomo , Y. , Grosset , D. G. , \u2026 Morris , H. R. ( 2023 ). Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia . Brain , 146 , 1873 \u2013 1887 . 36348503 103 Meneses , A. D. , Koga , S. , Li , Z. , O'leary , J. , Li , F. , Chen , K. , Murakami , A. , Qiao , W. , Kurti , A. , Heckman , M. G. , White , L. , Xie , M. , Chen , Y. , Finch , N. A. , Lim , M. J. , Delenclos , M. , Deture , M. A. , Linares , C. , Martin , N. B. , \u2026, Zhao , N. ( 2023 ). APOE2 exacerbates TDP\u201043 related toxicity in the absence of Alzheimer pathology . Annals of Neurology , 93 , 830 \u2013 843 . 36546684 104 Lee , H. , Aylward , A. J. , Pearse , R. V. , Lish , A. M. , Hsieh , Y.\u2010C. , Augur , Z. M. , Benoit , C. R. , Chou , V. , Knupp , A. , Pan , C. , Goberdhan , S. , Duong , D. M. , Seyfried , N. T. , Bennett , D. A. , Taga , M. F. , Huynh , K. , Arnold , M. , Meikle , P. J. , De Jager , P. L. , \u2026 Young\u2010Pearse , T. L. ( 2023 ). Cell\u2010type\u2010specific regulation of APOE and CLU levels in human neurons by the Alzheimer's disease risk gene SORL1 . Cell Reports , 42 , 112994 . 37611586 105 Mori , F. , Miki , Y. , Tanji , K. , Kakita , A. , Takahashi , H. , Utsumi , J. , Sasaki , H. , & Wakabayashi , K. ( 2015 ). Sortilin\u2010related receptor CNS expressed 2 (SorCS2) is localized to Bunina bodies in amyotrophic lateral sclerosis . Neuroscience Letters , 608 , 6 \u2013 11 . 26420026 106 Mishra , S. , Knupp , A. , Szabo , M. P. , Williams , C. A. , Kinoshita , C. , Hailey , D. W. , Wang , Y. , Andersen , O. M. , & Young , J. E. ( 2022 ). The Alzheimer's gene SORL1 is a regulator of endosomal traffic and recycling in human neurons . Cellular and Molecular Life Sciences , 79 , 162 . 35226190 107 Hung , C. , Tuck , E. , Stubbs , V. , Van Der Lee , S. J. , Aalfs , C. , Van Spaendonk , R. , Scheltens , P. , Hardy , J. , Holstege , H. , & Livesey , F. J. ( 2021 ). SORL1 deficiency in human excitatory neurons causes APP\u2010dependent defects in the endolysosome\u2010autophagy network . Cell Reports , 35 , 109259 . 34133918 108 Barthelson , K. , Pederson , S. M. , Newman , M. , & Lardelli , M. ( 2020 ). Brain transcriptome analysis reveals subtle effects on mitochondrial function and iron homeostasis of mutations in theSORL1gene implicated in early onset familial Alzheimer's disease . Molecular Brain , 13 , 142 . 33076949 109 Miners , J. S. , Clarke , P. , & Love , S. ( 2017 ). Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of A\u03b2 . Brain Pathology , 17 , 305 \u2013 313 . 110 Beeg , M. , Stravalaci , M. , Romeo , M. , Carr\u00e1 , A. D. , Cagnotto , A. , Rossi , A. , Diomede , L. , Salmona , M. , & Gobbi , M. ( 2016 ). Clusterin binds to A\u03b21\u201042 oligomers with high affinity and interferes with peptide aggregation by inhibiting primary and secondary nucleation . JBC , 291 , 6958 \u2013 6966 . 111 Naik , P. P. , Mukhopadhyay , S. , Praharaj , P. P. , Bhol , C. S. , Panigrahi , D. P. , Mahapatra , K. K. , Patra , S. , Saha , S. , Panda , A. K. , Panda , K. , Paul , S. , Aich , P. , Patra , S. K. , & Bhutia , S. K. ( 2021 ). Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway . Life Sciences , 264 , 118722 . 33160989 112 Satapathy , S. , Walker , H. , Brown , J. , Gambin , Y. , & Wilson , M. R. ( 2023 ). The N\u2010end rule pathway regulates ER stress\u2010induced clusterin release to the cytosol where it directs misfolded proteins for degradation . Cell Reports , 42 , 113059 . 37660295 113 Praharaj , P. P. , Patra , S. , Mishra , S. R. , Mukhopadhyay , S. , Klionsky , D. J. , Patil , S. , & Bhutia , S. K. ( 2023 ). CLU (clusterin) promotes mitophagic degradation of MSX2 through an AKT\u2010DNM1L/Drp1 axis to maintain SOX2\u2010mediated stemness in oral cancer stem cells . Autophagy , 19 , 2196 \u2013 2216 . 36779631 114 Hopfner , F. , Schulte , E. C. , Mollenhauer , B. , Bereznai , B. , Knauf , F. , Lichtner , P. , Zimprich , A. , Haubenberger , D. , Pirker , W. , Br\u00fccke , T. , Peters , A. , Gieger , C. , Kuhlenb\u00e4umer , G. , Trenkwalder , C. , & Winkelmann , J. ( 2013 ). The role of SCARB2 as susceptibility factor in Parkinson's disease . Movement Disorders , 28 , 538 \u2013 540 . 23408458 115 Navarro\u2010Romero , A. , Fernandez\u2010Gonzalez , I. , Riera , J. , Montpeyo , M. , Albert\u2010Bayo , M. , Lopez\u2010Royo , T. , Castillo\u2010Sanchez , P. , Carnicer\u2010Caceres , C. , Arranz\u2010Amo , J. A. , Castillo\u2010Ribelles , L. , Pradas , E. , Casas , J. , Vila , M. , & Martinez\u2010Vicente , M. ( 2022 ). Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone\u2010mediated\u2010autophagy deficiency, and alpha\u2010synuclein pathology . NPJ Parkinson's disease , 8 , 126 . 116 Trinchera , R. , & Indellicato , M. ( 2019 ). The link between gaucher disease and parkinson's disease sheds light on old and novel disorders of sphingolipid metabolism . International Journal of Molecular Sciences , 20 , 3304 . 31284408 117 Reczek , D. , Schwake , M. , Schr\u00f6der , J. , Hughes , H. , Blanz , J. , Jin , X. , Brondyk , W. , Van Patten , S. , Edmunds , T. , & Saftig , P. ( 2007 ). LIMP\u20102 is a receptor for lysosomal mannose\u20106\u2010phosphate\u2010independent targeting of beta\u2010glucocerebrosidase . Cell , 131 , 770 \u2013 783 . 18022370 118 Heybrock , S. , Kanerva , K. , Meng , Y. , Ing , C. , Liang , A. , Xiong , Z.\u2010J. , Weng , X. , Ah Kim , Y. , Collins , R. , Trimble , W. , Pom\u00e8s , R. , Priv\u00e9 , G. G. , Annaert , W. , Schwake , M. , Heeren , J. , L\u00fcllmann\u2010Rauch , R. , Grinstein , S. , Ikonen , E. , Saftig , P. , & Neculai , D. ( 2019 ). Lysosomal integral membrane protein\u20102 (LIMP\u20102/SCARB2) is involved in lysosomal cholesterol export . Nature Communications , 10 , 3521 . 119 Zou , Y. , Pei , J. , Wang , Y. , Chen , Q. , Sun , M. , Kang , L. , Zhang , X. , Zhang , L. , Gao , X. , & Lin , Z. ( 2022 ). The deficiency of SCARB2/LIMP\u20102 impairs metabolism via disrupted mTORC1\u2010dependent mitochondrial OXPHOS . International Journal of Molecular Sciences , 23 , 8634 . 35955761 120 Van Veen , S. , Martin , S. , Van Den Haute , C. , Benoy , V. , Lyons , J. , Vanhoutte , R. , Kahler , J. P. , Decuypere , J.\u2010P. , Gelders , G. , Lambie , E. , Zielich , J. , Swinnen , J. V. , Annaert , W. , Agostinis , P. , Ghesqui\u00e8re , B. , Verhelst , S. , Baekelandt , V. , Eggermont , J. , & Vangheluwe , P. ( 2020 ). ATP13A2 deficiency disrupts lysosomal polyamine export . Nature , 578 , 419 \u2013 424 . 31996848 121 Azfar , M. , van Veen , S. , Houdou , M. , Hamouda , N. N. , Eggermont , J. , & Vangheluwe , P. ( 2022 ). P5B\u2010ATPases in the mammalian polyamine transport system and their role in disease . Biochimica et Biophysica Acta (BBA) \u2010 Molecular Cell Research , 1869 , 119354 . 36064065 122 Vrijsen , S. , Besora\u2010Casals , L. , Van Veen , S. , Zielich , J. , Van Den Haute , C. , Hamouda , N. N. , Fischer , C. , Ghesqui\u00e8re , B. , Tournev , I. , Agostinis , P. , Baekelandt , V. , Eggermont , J. , Lambie , E. , Martin , S. , & Vangheluwe , P. ( 2020 ). ATP13A2\u2010mediated endo\u2010lysosomal polyamine export counters mitochondrial oxidative stress . National Academy of Sciences , 117 , 31198 \u2013 31207 . 123 T Vicente , C. , Perneel , J. , Wynants , S. , Heeman , B. , Van Den Broeck , M. , Baker , M. , Cheung , S. , Faura , J. , Mackenzie , I. R. A. , & Rademakers , R. ( 2023 ). C\u2010terminal TMEM106B fragments in human brain correlate with disease\u2010associated TMEM106B haplotypes . Brain , 146 , 4055 \u2013 4064 . 37100087 124 Tropea , T. F. , Mak , J. , Guo , M. H. , Xie , S. X. , Suh , E. , Rick , J. , Siderowf , A. , Weintraub , D. , Grossman , M. , Irwin , D. , Wolk , D. A. , Trojanowski , J. Q. , Van Deerlin , V. , & Chen\u2010Plotkin , A. S. ( 2019 ). TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia . Annals of Neurology , 85 , 801 \u2013 811 . 30973966 125 Bauer , C. S. , Webster , C. P. , Shaw , A. C. , Kok , J. R. , Castelli , L. M. , Lin , Y.\u2010H. , Smith , E. F. , Illanes\u2010\u00c1lvarez , F. , Higginbottom , A. , Shaw , P. J. , Azzouz , M. , Ferraiuolo , L. , Hautbergue , G. M. , Grierson , A. J. , & De Vos , K. J. ( 2022 ). Loss of TMEM106B exacerbates C9ALS/FTD DPR pathology by disrupting autophagosome maturation . Frontiers in Cellular Neuroscience , 16 , 1061559 . 36619668 126 L\u00fcningschr\u00f6r , P. , Werner , G. , Stroobants , S. , Kakuta , S. , Dombert , B. , Sinske , D. , Wanner , R. , L\u00fcllmann\u2010Rauch , R. , Wefers , B. , Wurst , W. , D'hooge , R. , Uchiyama , Y. , Sendtner , M. , Haass , C. , Saftig , P. , Kn\u00f6ll , B. , Capell , A. , & Damme , M. ( 2020 ). The FTLD risk factor TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons . Cell Reports , 30 , 3506 \u2013 3519.e6 . 32160553 127 Suzuki , H. , & Matsuoka , M. ( 2014 ). The lysosomal trafficking transmembrane protein 106B is linked to cell death . JBC , 291 , 21448 \u2013 21460 . 128 Lee , R. G. , Rudler , D. L. , Raven , S. A. , Peng , L. , Chopin , A. , Moh , E. S. X. , Mccubbin , T. , Siira , S. J. , Fagan , S. V. , Debono , N. J. , Stentenbach , M. , Browne , J. , Rackham , F. F. , Li , J. , Simpson , K. J. , Marcellin , E. , Packer , N. H. , Reid , G. E. , Padman , B. S. , \u2026 Filipovska , A. ( 2024 ). Quantitative subcellular reconstruction reveals a lipid mediated inter\u2010organelle biogenesis network . Nature Cell Biology , 26 , 57 \u2013 71 . 38129691 129 De Pace , R. , Maroofian , R. , Paimboeuf , A. , Zamani , M. , Zaki , M. S. , Sadeghian , S. , Azizimalamiri , R. , Galehdari , H. , Zeighami , J. , Williamson , C. D. , Fleming , E. , Zhou , D. , Gannon , J. L. , Thiffault , I. , Roze , E. , Suri , M. , Zifarelli , G. , Bauer , P. , Houlden , H. , \u2026 Bonifacino , J. S. ( 2023 ). Biallelic BORCS8 variants cause an infantile\u2010onset neurodegenerative disorder with altered lysosome dynamics . Brain , awad427 . 130 De Pace , R. , Ghosh , S. , Ryan , V. H. , Sohn , M. , Jarnik , M. , Rezvan Sangsari , P. , Morgan , N. Y. , Dale , R. K. , Ward , M. E. , & Bonifacino , J. S. ( 2024 ). Messenger RNA transport on lysosomal vesicles maintains axonal mitochondrial homeostasis and prevents axonal degeneration . Nature Neuroscience , 27 , 1087 \u2013 1102 . 38600167 131 Boland , B. , Kumar , A. , Lee , S. , Platt , F. M. , Wegiel , J. , Yu , W. H. , & Nixon , R. A. ( 2008 ). Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer's disease . Journal of Neuroscience , 28 , 6926 \u2013 6937 . 18596167 132 Garc\u00eda\u2010Sanz , P. , Orgaz , L. , Fuentes , J. M. , Vicario , C. , & Moratalla , R. ( 2018 ). Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA\u2010Parkinson disease . Autophagy , 14 , 717 \u2013 718 . 29368986 133 Rogers , R. S. , Tungtur , S. , Tanaka , T. , Nadeau , L. L. , Badawi , Y. , Wang , H. , Ni , H.\u2010M. , Ding , W.\u2010X. , & Nishimune , H. ( 2017 ). Impaired mitophagy plays a role in denervation of neuromuscular junctions in ALS mice . Frontiers in Neuroscience , 11 , 473 . 28890682 134 Hariri , M. , Millane , G. , Guimond , M. P. , Guay , G. , Dennis , J. W. , & Nabi , I. R. ( 2000 ). Biogenesis of multilamellar bodies via autophagy . Molecular Biology of the Cell , 11 , 255 \u2013 268 . 10637306 135 Cacace , R. , Hoogmartens , J. , Hens , E. , Buist , A. , Cras , P. , Sieben , A. , Vandenberghe , R. , Engelborghs , S. , De Deyn , P. P. , Martin , J.\u2010J. , Moechars , D. , & Van Broeckhoven , C. ( 2020 ). A family\u2010based genetic study identifies mutations in TLR9 impairing receptor activation: A role for innate immunity in AD pathogenesis . Alzheimer's Dementia , 16 , e047212 . 136 Skopelja\u2010Gardner , S. , An , J. , & Elkon , K. B. ( 2022 ). Role of the cGAS\u2010STING pathway in systemic and organ\u2010specific diseases . Nature Reviews Nephrology , 18 , 558 \u2013 572 . 35732833 137 Xie , X. , Ma , G. , Li , X. , Zhao , J. , Zhao , Z. , & Zeng , J. ( 2023 ). Activation of innate immune cGAS\u2010STING pathway contributes to Alzheimer's pathogenesis in 5\u00d7FAD mice . Nature Aging , 3 , 202 \u2013 212 . 37118112 138 Hou , Y. , Wei , Y. , Lautrup , S. , Yang , B. , Wang , Y. , Cordonnier , S. , Mattson , M. P. , Croteau , D. L. , & Bohr , V. A. ( 2021 ). NAD + supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS\u2010STING . The Proceedings of the National Academy of Sciences USA. , 118 , e2011226118 . 139 Du , H. , Wong , M. Y. , Zhang , T. , Santos , M. N. , Hsu , C. , Zhang , J. , Yu , H. , Luo , W. , & Hu , F. ( 2021 ). A multifaceted role of progranulin in regulating amyloid\u2010beta dynamics and responses . Life Science Alliance , 4 , e202000874 . 34103390 140 Davis , O. B. , Shin , H. R. , Lim , C.\u2010Y. , Wu , E. Y. , Kukurugya , M. , Maher , C. F. , Perera , R. M. , Ordonez , M. P. , & Zoncu , R. ( 2021 ). NPC1\u2010mTORC1 signaling couples cholesterol sensing to organelle homeostasis and is a targetable pathway in niemann\u2010Pick Type C . Developmental Cell , 56 , 260 \u2013 276.e7 . 10.1016/j.devcel.2020.11.016 33308480 141 Nazmi , A. , Field , R. H. , Griffin , E. W. , Haugh , O. , Hennessy , E. , Cox , D. , Reis , R. , Tortorelli , L. , Murray , C. L. , Lopez\u2010Rodriguez , A. B. , Jin , L. , Lavelle , E. C. , Dunne , A. , & Cunningham , C. ( 2019 ). Chronic neurodegeneration induces type I interferon synthesis via STING, shaping microglial phenotype and accelerating disease progression . Glia , 67 , 1254 \u2013 1276 . 30680794 142 Chu , T. T. , Tu , X. , Yang , K. , Wu , J. , Repa , J. J. , & Yan , N. ( 2021 ). Tonic prime\u2010boost of STING signalling mediates Niemann\u2010Pick disease type C . Nature , 596 , 570 \u2013 575 . 34290407 143 Tan , H. Y. , Yong , Y. K. , Xue , Y. C. , Liu , H. , Furihata , T. , Shankar , E. M. , & Ng , C. S. ( 2022 ). cGAS and DDX41\u2010STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model . Iscience , 25 , 104404 . 35712074 144 Gallagher , E. R. , & Holzbaur , E. L. F. ( 2023 ). The selective autophagy adaptor p62/SQSTM1 forms phase condensates regulated by HSP27 that facilitate the clearance of damaged lysosomes via lysophagy . Cell Reports , 42 , 112037 . 36701233 145 Bonet\u2010Ponce , L. , Beilina , A. , Williamson , C. D. , Lindberg , E. , Kluss , J. H. , Saez\u2010Atienzar , S. , Landeck , N. , Kumaran , R. , Mamais , A. , Bleck , C. K. E. , Li , Y. , & Cookson , M. R. ( 2020 ). LRRK2 mediates tubulation and vesicle sorting from lysosomes . Science Advances , 6 , eabb2454 . 33177079 146 Sharma , M. , Ioannidis , J. P. A. , Aasly , J. O. , Annesi , G. , Brice , A. , Van Broeckhoven , C. , Bertram , L. , Bozi , M. , Crosiers , D. , Clarke , C. , Facheris , M. , Farrer , M. , Garraux , G. , Gispert , S. , Auburger , G. , Vilari\u00f1o\u2010G\u00fcell , C. , Hadjigeorgiou , G. M. , Hicks , A. A. , Hattori , N. , \u2026 Uitti , R. J. ( 2012 ). Large\u2010scale replication and heterogeneity in Parkinson disease genetic loci . Neurology , 79 , 659 \u2013 667 . 22786590 147 Tanaka , T. , Warner , B. M. , Michael , D. G. , Nakamura , H. , Odani , T. , Yin , H. , Atsumi , T. , Noguchi , M. , & Chiorini , J. A. ( 2022 ). LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization . Autophagy , 18 , 1629 \u2013 1647 . 34802379 148 Gaband\u00e9\u2010Rodr\u00edguez , E. , P\u00e9rez\u2010Ca\u00f1am\u00e1s , A. , Soto\u2010Huelin , B. , Mitroi , D. N. , S\u00e1nchez\u2010Redondo , S. , Mart\u00ednez\u2010S\u00e1ez , E. , Venero , C. , Peinado , H. , & Ledesma , M. D. ( 2019 ). Lipid\u2010induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders . Embo Journal , 38 , e99553 . 30530526 149 Hancock\u2010Cerutti , W. , Wu , Z. , Xu , P. , Yadavalli , N. , Leonzino , M. , Tharkeshwar , A. K. , Ferguson , S. M. , Shadel , G. S. , & De Camilli , P. ( 2022 ). ER\u2010lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA\u2010dependent STING signaling . Journal of Cell Biology , 221 , e202106046 . 35657605 150 Yu , C.\u2010H. , Davidson , S. , Harapas , C. R. , Hilton , J. B. , Mlodzianoski , M. J. , Laohadonkul , P. , Louis , C. , Low , R. R. J. , Moecking , J. , De Nardo , D. , Balka , K. R. , Calleja , D. J. , Moghaddas , F. , Ni , E. , Mclean , C. A. , Samson , A. L. , Tyebji , S. , Tonkin , C. J. , Bye , C. R. , \u2026 Masters , S. L. ( 2020 ). TDP\u201043 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS . Cell , 183 , 636 \u2013 649.e18 .e18. 33031745 151 Samanta , S. , Akhter , F. , Roy , A. , Chen , D. , Turner , B. , Wang , Y. , Clemente , N. , Wang , C. , Swerdlow , R. H. , Battaile , K. P. , Lovell , S. , Yan , S. F. , & Yan , S. S. ( 2024 ). New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease . Brain , 147 , 1710 \u2013 1725 . 38146639 152 Sliter , D. A. , Martinez , J. , Hao , L. , Chen , X. , Sun , N. , Fischer , T. D. , Burman , J. L. , Li , Y. , Zhang , Z. , Narendra , D. P. , Cai , H. , Borsche , M. , Klein , C. , & Youle , R. J. ( 2018 ). Parkin and PINK1 mitigate STING\u2010induced inflammation . Nature , 561 , 258 \u2013 262 . 30135585 153 Hinkle , J. T. , Patel , J. , Panicker , N. , Karuppagounder , S. S. , Biswas , D. , Belingon , B. , Chen , R. , Brahmachari , S. , Pletnikova , O. , Troncoso , J. C. , Dawson , V. L. , & Dawson , T. M. ( 2022 ). STING mediates neurodegeneration and neuroinflammation in nigrostriatal \u03b1\u2010synucleinopathy . PNAS U S A , 119 , 1 \u2013 8 . 154 Devi , L. , Raghavendran , V. , Prabhu , B. M. , Avadhani , N. G. , & Anandatheerthavarada , H. K. ( 2008 ). Anandatheerthavarada HK. Mitochondrial import and accumulation of \u03b1\u2010synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain . JBC , 283 , 9089 \u2013 9100 . 155 Chinta , S. J. , Mallajosyula , J. K. , Rane , A. , & Andersen , J. K. ( 2010 ). Mitochondrial alpha\u2010synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo . Neuroscience Letters , 486 , 235 \u2013 239 . 20887775 156 Pozo Devoto , V. M. , & Falzone , T. L. ( 2017 ). Mitochondrial dynamics in Parkinson's disease: A role for \u03b1\u2010synuclein? DMM Disease Models & Mechanisms , 10 , 1075 \u2013 87 . 28883016 157 Brundin , P. , Melki , R. , & Kopito , R. ( 2010 ). Prion\u2010like transmission of protein aggregates in neurodegenerative diseases . Nature Reviews Molecular Cell Biology , 11 , 301 \u2013 307 . 20308987 158 Magr\u00ec , A. , Lipari , C. L. R. , Risiglione , P. , Zimbone , S. , Guarino , F. , Caccamo , A. , & Messina , A. ( 2023 ). ERK1/2\u2010dependent TSPO overactivation associates with the loss of mitophagy and mitochondrial respiration in ALS . Cell Death & Disease , 14 , 122 . 36792609 159 Gulen , M. F. , Samson , N. , Keller , A. , Schwabenland , M. , Liu , C. , Gl\u00fcck , S. , Thacker , V. V. , Favre , L. , Mangeat , B. , Kroese , L. J. , Krimpenfort , P. , Prinz , M. , & Ablasser , A. ( 2023 ). cGAS\u2010STING drives ageing\u2010related inflammation and neurodegeneration . Nature , 620 , 374 \u2013 380 . 37532932 160 Gordaliza\u2010Alaguero , I. , Cant\u00f3 , C. , & Zorzano , A. ( 2019 ). Metabolic implications of organelle\u2010mitochondria communication . Embo Reports , 20 , e47928 . 31418169 161 Prinz , W. A. , Toulmay , A. , & Balla , T. ( 2020 ). The functional universe of membrane contact sites . Nature Reviews Molecular Cell Biology , 21 , 7 \u2013 24 . 31732717 162 Cisneros , J. , Belton , T. B. , Shum , G. C. , Molakal , C. G. , & Wong , Y. C. ( 2022 ). Mitochondria\u2010lysosome contact site dynamics and misregulation in neurodegenerative diseases . Trends in Neuroscience (Tins) , 45 , 312 \u2013 322 . 163 Wong , Y. C. , Ysselstein , D. , & Krainc , D. ( 2018 ). Mitochondria\u2013lysosome contacts regulate mitochondrial fission via RAB7 GTP hydrolysis . Nature , 554 , 382 \u2013 386 . 29364868 164 Wong , Y. C. , Peng , W. , & Krainc , D. ( 2019 ). Lysosomal regulation of inter\u2010mitochondrial contact fate and motility in charcot\u2010marie\u2010tooth type 2 . Developmental Cell , 50 , 339 \u2013 354.e4 .e4. 31231042 165 Cantarero , L. , Ju\u00e1rez\u2010Escoto , E. , Civera\u2010Treg\u00f3n , A. , Rodr\u00edguez\u2010Sanz , M. , Rold\u00e1n , M. , Ben\u00edtez , R. , Hoenicka , J. , & Palau , F. ( 2021 ). Mitochondria\u2010lysosome membrane contacts are defective in GDAP1\u2010related Charcot\u2010Marie\u2010Tooth disease . Human Molecular Genetics , 29 , 3589 \u2013 3605 . 33372681 166 Filadi , R. , Pendin , D. , & Mitofusin , P. P. ( 2018 ). 2: from functions to disease . Cell Death & Disease , 9 , 330 . 29491355 167 Peng , W. , Wong , Y. C. , & Krainc , D. ( 2020 ). Mitochondria\u2010lysosome contacts regulate mitochondrial Ca 2+ dynamics via lysosomal TRPML1 . The Proceedings of the National Academy of Sciences USA. , 117 , 19266 \u2013 19275 . 168 Tharkeshwar , A. K. , Trekker , J. , Vermeire , W. , Pauwels , J. , Sannerud , R. , Priestman , D. A. , Te Vruchte , D. , Vints , K. , Baatsen , P. , Decuypere , J.\u2010P. , Lu , H. , Martin , S. , Vangheluwe , P. , Swinnen , J. V. , Lagae , L. , Impens , F. , Platt , F. M. , Gevaert , K. , & Annaert , W. ( 2017 ). A novel approach to analyze lysosomal dysfunctions through subcellular proteomics and lipidomics: The case of NPC1 deficiency . Scientific Reports , 7 , 41408 . 10.1038/srep41408 28134274 169 H\u00f6glinger , D. , Burgoyne , T. , Sanchez\u2010Heras , E. , Hartwig , P. , Colaco , A. , Newton , J. , Futter , C. E. , Spiegel , S. , Platt , F. M. , & Eden , E. R. ( 2019 ). NPC1 regulates ER contacts with endocytic organelles to mediate cholesterol egress . Nature Communications , 10 , 4276 . 10.1038/s41467-019-12152-2 170 Kim , S. , Wong , Y. C. , Gao , F. , & Krainc , D. ( 2021 ). Dysregulation of mitochondria\u2010lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease . Nature Communications , 12 , 1807 . 171 Rabas , N. , Palmer , S. , Mitchell , L. , Ismail , S. , Gohlke , A. , Riley , J. S. , Tait , S. W. G. , Gammage , P. , Soares , L. L. , Macpherson , I. R. , & Norman , J. C. ( 2021 ). PINK1 drives production of mtDNA\u2010containing extracellular vesicles to promote invasiveness . Journal of Cell Biology , 220 , e202006049 . 34623384 172 Smolders , S. , Philtjens , S. , Crosiers , D. , Sieben , A. , Hens , E. , Heeman , B. , Van Mossevelde , S. , Pals , P. , Asselbergh , B. , Dos Santos Dias , R. , Vermeiren , Y. , Vandenberghe , R. , Engelborghs , S. , De Deyn , P. P. , Martin , J.\u2010J. , Cras , P. , Annaert , W. , & Van Broeckhoven , C. ( 2021 ). Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease . Acta Neuropathologica Communications , 9 , 25 . 33579389 173 Kumar , N. , Leonzino , M. , Hancock\u2010Cerutti , W. , Horenkamp , F. A. , Li , P. , Lees , J. A. , Wheeler , H. , Reinisch , K. M. , & De Camilli , P. ( 2018 ). VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites . Journal of Cell Biology , 217 , 3625 \u2013 3639 . 30093493 174 Guill\u00e9n\u2010Samander , A. , & De Camilli , P. ( 2023 ). Endoplasmic reticulum membrane contact sites, lipid transport, and neurodegeneration . Cold Spring Harbor Perspectives in Biology , 15 , a041257 . 36123033 175 Rampoldi , L. , Dobson\u2010Stone , C. , Rubio , J. P. , Danek , A. , Chalmers , R. M. , Wood , N. W. , Verellen , C. , Ferrer , X. , Malandrini , A. , Fabrizi , G. M. , Brown , R. , Vance , J. , Pericak\u2010Vance , M. , Rudolf , G. , Carr\u00e8 , S. , Alonso , E. , Manfredi , M. , N\u00e9meth , A. H. , & Monaco , A. P. ( 2001 ). A conserved sorting\u2010associated protein is mutant in chorea\u2010acanthocytosis . Nature Genetics , 28 , 119 \u2013 120 . 11381253 176 Ueno , S.\u2010I. , Maruki , Y. , Nakamura , M. , Tomemori , Y. , Kamae , K. , Tanabe , H. , Yamashita , Y. , Matsuda , S. , Kaneko , S. , & Sano , A. ( 2001 ). The gene encoding a newly discovered protein, chorein, is mutated in chorea\u2010acanthocytosis . Nature Genetics , 28 , 121 \u2013 122 . 11381254 177 Yeshaw , W. M. , Van Der Zwaag , M. , Pinto , F. , Lahaye , L. L. , Faber , A. I. , G\u00f3mez\u2010S\u00e1nchez , R. , Dolga , A. M. , Poland , C. , Monaco , A. P. , Van Ijzendoorn , S. C. , Grzeschik , N. A. , Velayos\u2010Baeza , A. , & Sibon , O. C. ( 2019 ). Human VPS13A is associated with multiple organelles and influences mitochondrial morphology and lipid droplet motility . Elife , 8 , 1 \u2013 37 . 178 Lesage , S. , Drouet , V. , Majounie , E. , Deramecourt , V. , Jacoupy , M. , Nicolas , A. , Cormier\u2010Dequaire , F. , Hassoun , S. M. , Pujol , C. , Ciura , S. , Erpapazoglou , Z. , Usenko , T. , Maurage , C.\u2010A. , Sahbatou , M. , Liebau , S. , Ding , J. , Bilgic , B. , Emre , M. , Erginel\u2010Unaltuna , N. , \u2026 Guven , G. ( 2016 ). Loss of VPS13C function in autosomal\u2010recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin\u2010Dependent mitophagy . American Journal of Human Genetics , 98 , 500 \u2013 513 . 10.1016/j.ajhg.2016.01.014 26942284 179 Pera , M. , Larrea , D. , Guardia\u2010Laguarta , C. , Montesinos , J. , Velasco , K. R. , Agrawal , R. R. , Xu , Y. , Chan , R. B. , Di Paolo , G. , Mehler , M. F. , Perumal , G. S. , Macaluso , F. P. , Freyberg , Z. Z. , Acin\u2010Perez , R. , Enriquez , J. A. , Schon , E. A. , & Area\u2010Gomez , E. ( 2017 ). Increased localization of APP\u2010C99 in mitochondria\u2010associated ER membranes causes mitochondrial dysfunction in Alzheimer disease . Embo Journal , 36 , 3356 \u2013 3371 . 29018038 180 Bhattacharyya , R. , Black , S. E. , Lotlikar , M. S. , Fenn , R. H. , Jorfi , M. , Kovacs , D. M. , & Tanzi , R. E. ( 2021 ). Axonal generation of amyloid\u2010\u03b2 from palmitoylated APP in mitochondria\u2010associated endoplasmic reticulum membranes . Cell reports , 35 , 109134 . 34010653 181 Sannerud , R. , Esselens , C. , Ejsmont , P. , Mattera , R. , Rochin , L. , Tharkeshwar , A. K. , De Baets , G. , De Wever , V. , Habets , R. , Baert , V. , Vermeire , W. , Michiels , C. , Groot , A. J. , Wouters , R. , Dillen , K. , Vints , K. , Baatsen , P. , Munck , S. , Derua , R. , \u2026 Annaert , W. ( 2016 ). Restricted location of PSEN2/\u03b3\u2010secretase determines substrate specificity and generates an intracellular A\u03b2 Pool . Cell , 166 , 193 \u2013 208 . 10.1016/j.cell.2016.05.020 27293189 182 Sannerud , R. , Declerck , I. , Peric , A. , Raemaekers , T. , Menendez , G. , Zhou , L. , Veerle , B. , Coen , K. , Munck , S. , De Strooper , B. , Schiavo , G. , & Annaert , W. ( 2011 ). ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1 . PNAS U S A , 108 , E559 \u2013 68 . 10.1073/pnas.1100745108 183 Kwart , D. , Gregg , A. , Scheckel , C. , Murphy , E. A. , Paquet , D. , Duffield , M. , Fak , J. , Olsen , O. , Darnell , R. B. , & Tessier\u2010Lavigne , M. ( 2019 ). A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP \u03b2\u2010CTFs, Not A\u03b2 . Neuron , 104 , 1022 . 31805257 184 Hung , C. O. Y. , & Livesey , F. J. ( 2018 ). Altered \u03b3\u2010secretase processing of APP disrupts lysosome and autophagosome function in monogenic Alzheimer's Disease . Cell Reports , 25 , 3647 \u2013 3660.e2 . 10.1016/j.celrep.2018.11.095 30590039 185 Fedeli , C. , Filadi , R. , Rossi , A. , Mammucari , C. , & Pizzo , P. ( 2019 ). PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca2+ homeostasis . Autophagy , 15 , 2044 \u2013 2062 . 10.1080/15548627.2019.1596489 30892128 186 Mart\u00edn\u2010Maestro , P. , Gargini , R. , A Sproul , A. , Garc\u00eda , E. , Ant\u00f3n , L. C. , Noggle , S. , Arancio , O. , Avila , J. , & Garc\u00eda\u2010Escudero , V. ( 2017 ). Mitophagy failure in fibroblasts and iPSC\u2010derived neurons of Alzheimer's disease\u2010associated presenilin 1 mutation . Frontiers in Molecular Neuroscience , 10 , 291 . 28959184 187 Coffey , E. E. , Beckel , J. M. , Laties , A. M. , & Mitchell , C. H. ( 2014 ). Lysosomal alkalization and dysfunction in human fibroblasts with the Alzheimer's disease\u2010linked presenilin 1 A246E mutation can be reversed with cAMP . Neuroscience , 263 , 111 \u2013 124 . 24418614 188 Thimiri Govinda Raj , D. B. , Ghesqui\u00e8re , B. , Tharkeshwar , A. K. , Coen , K. , Derua , R. , Vanderschaeghe , D. , Rysman , E. , Bagadi , M. , Baatsen , P. , De Strooper , B. , Waelkens , E. , Borghs , G. , Callewaert , N. , Swinnen , J. , Gevaert , K. , & Annaert , W. ( 2014 ). A novel strategy for the comprehensive analysis of the biomolecular composition of isolated plasma membranes . Molecular Systems Biology , 7 , 541 \u2013 541 . 10.1038/msb.2011.74 189 Esselens , C. , Oorschot , V. , Baert , V. , Raemaekers , T. , Spittaels , K. , Serneels , L. , Zheng , H. , Saftig , P. , De Strooper , B. , Klumperman , J. , & Annaert , W. ( 2004 ). Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway . Journal of Cell Biology , 166 , 1041 \u2013 1054 . 10.1083/jcb.200406060 15452145 190 Du , H. , Guo , L. , Yan , S. , Sosunov , A. A. , Mckhann , G. M. , & Shidu Yan , S. ( 2010 ). Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model . PNAS , 107 , 18670 \u2013 18675 . 20937894 191 Georgakopoulos , N. D. , Wells , G. , & Campanella , M. ( 2017 ). The pharmacological regulation of cellular mitophagy . Nature Chemical Biology , 13 , 136 \u2013 146 . 28103219 192 Du , F. , Yu , Q. , Yan , S. , Hu , G. , Lue , L.\u2010F. , Walker , D. G. , Wu , L. , Yan , S. F. , Tieu , K. , & Yan , S. S. ( 2017 ). PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease . Brain , 140 , 3233 \u2013 3251 . 29077793 193 Narendra , D. , Tanaka , A. , Suen , D.\u2010F. , & Youle , R. J. ( 2008 ). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy . Journal of Cell Biology , 183 , 795 \u2013 803 . 19029340 194 Cho , I. , Song , H.\u2010O. , Ji , H. E. , Yang , S. , & Cho , J. H. ( 2022 ). BAM15 relieves neurodegeneration in aged caenorhabditis elegans and extends lifespan . Metabolites , 12 , 1129 . 36422268 195 Goudarzi , S. , Hosseini , A. , Abdollahi , M. , & Haghi\u2010Aminjan , H. ( 2021 ). Insights into parkin\u2010mediated mitophagy in Alzheimer's disease: A systematic review . Frontiers in Aging Neuroscience , 13 , 674071 . 34393755 196 Masaldan , S. , Callegari , S. , & Dewson , G. ( 2022 ). Therapeutic targeting of mitophagy in Parkinson's disease . Biochemical Society Transactions , 50 , 783 \u2013 797 . 35311891 197 Arotcarena , M.\u2010L. , Soria , F. N. , Cunha , A. , Doudnikoff , E. , Pr\u00e9vot , G. , Daniel , J. , Blanchard\u2010Desce , M. , Barth\u00e9l\u00e9my , P. , Bezard , E. , Crauste\u2010Manciet , S. , & Dehay , B. ( 2022 ). Acidic nanoparticles protect against \u03b1\u2010synuclein\u2010induced neurodegeneration through the restoration of lysosomal function . Aging Cell , 21 , e13584 . 35318803 198 Jiang , Y. , Sato , Y. , Im , E. , Berg , M. , Bordi , M. , Darji , S. , Kumar , A. , Mohan , P. S. , Bandyopadhyay , U. , Diaz , A. , Cuervo , A. M. , & Nixon , R. A. ( 2019 ). Lysosomal dysfunction in down syndrome is APP\u2010dependent and mediated by APP\u2010\u03b2CTF (C99) . Journal of Neuroscience , 39 , 5255 \u2013 5268 . 31043483 199 Zeng , J. , Acin\u2010Perez , R. , Assali , E. A. , Martin , A. , Brownstein , A. J. , Petcherski , A. , Fern\u00e1ndez\u2010Del\u2010Rio , L. , Xiao , R. , Lo , C. H. , Shum , M. , Liesa , M. , Han , X. , Shirihai , O. S. , & Grinstaff , M. W. ( 2023 ). Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non\u2010alcoholic fatty liver disease . Nature Communications , 14 , 2573 . 200 Ma , T. , Tian , X. , Zhang , B. , Li , M. , Wang , Y. , Yang , C. , Wu , J. , Wei , X. , Qu , Q. , Yu , Y. , Long , S. , Feng , J.\u2010W. , Li , C. , Zhang , C. , Xie , C. , Wu , Y. , Xu , Z. , Chen , J. , Yu , Y. , \u2026 Lin , S.\u2010C. ( 2022 ). Low\u2010dose metformin targets the lysosomal AMPK pathway through PEN2 . Nature , 603 , 159 \u2013 165 . 35197629 201 Richter , F. , Fleming , S. M. , Watson , M. , Lemesre , V. , Pellegrino , L. , Ranes , B. , Zhu , C. , Mortazavi , F. , Mulligan , C. K. , Sioshansi , P. C. , Hean , S. , De La Rosa , K. , Khanna , R. , Flanagan , J. , Lockhart , D. J. , Wustman , B. A. , Clark , S. W. , & Chesselet , M.\u2010F. ( 2014 ). A GCase chaperone improves motor function in a mouse model of synucleinopathy . Neurotherapeutics , 11 , 840 \u2013 856 . 25037721 202 Mullin , S. , Smith , L. , Lee , K. , D'souza , G. , Woodgate , P. , Elflein , J. , H\u00e4llqvist , J. , Toffoli , M. , Streeter , A. , Hosking , J. , Heywood , W. E. , Khengar , R. , Campbell , P. , Hehir , J. , Cable , S. , Mills , K. , Zetterberg , H. , Limousin , P. , Libri , V. , \u2026 Schapira , A. H. V. ( 2020 ). Ambroxol for the treatment of patients with parkinson disease with and without glucocerebrosidase gene mutations: A nonrandomized, noncontrolled trial . JAMA neurology , 77 , 427 \u2013 434 . 31930374 203 Giladi , N. , Alcalay , R. N. , Cutter , G. , Gasser , T. , Gurevich , T. , H\u00f6glinger , G. U. , Marek , K. , Pacchetti , C. , Schapira , A. H. V. , Scherzer , C. R. , Simuni , T. , Minini , P. , Sardi , S. P. , & Peterschmitt , M. J. ( 2023 ). Safety and efficacy of venglustat in GBA1\u2010associated Parkinson's disease: An international, multicentre, double\u2010blind, randomised, placebo\u2010controlled, phase 2 trial . Lancet Neurology , 22 , 661 \u2013 671 . 37479372 204 Peng , X. , Holler , C. J. , Alves , A.\u2010M. F. , Oliviera , M. G. , Speake , M. , Pugliese , A. , Oskouei , M. R. , de Freitas , I. D. , Chen , A. Y. , Gallegos , R. , McTighe , S. M. , Koenig , G. , Hurst , R. S. , Blain , J. F. , Lanter , J. C. , & Burnett , D. A. ( 2024 ). Discovery and characterization of novel TRPML1 agonists . Bioorganic & Medicinal Chemistry Letters , 98 , 129595 . 38141860 205 Bonam , S. R. , Wang , F. , & Muller , S. ( 2019 ). Lysosomes as a therapeutic target . Nat Rev Drug Discovery , 18 , 923 \u2013 948 . 31477883 206 Marques , A. R. A. , Di Spiezio , A. , Thie\u00dfen , N. , Schmidt , L. , Gr\u00f6tzinger , J. , L\u00fcllmann\u2010Rauch , R. , Damme , M. , Storck , S. E. , Pietrzik , C. U. , Fogh , J. , B\u00e4r , J. , Mikhaylova , M. , Glatzel , M. , Bassal , M. , Bartsch , U. , & Saftig , P. ( 2019 ). Enzyme replacement therapy with recombinant pro\u2010CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis . Autophagy , 16 , 811 \u2013 825 . 31282275 207 Prieto Huarcaya , S. , Drobny , A. , Marques , A. R. A. , Di Spiezio , A. , Dobert , J. P. , Balta , D. , Werner , C. , Rizo , T. , Gallwitz , L. , Bub , S. , Stojkovska , I. , Belur , N. R. , Fogh , J. , Mazzulli , J. R. , Xiang , W. , Fulzele , A. , Dejung , M. , Sauer , M. , Winner , B. , \u2026 Zunke , F. ( 2022 ). Recombinant pro\u2010CTSD (cathepsin D) enhances SNCA/\u03b1\u2010Synuclein degradation in \u03b1\u2010Synucleinopathy models . Autophagy , 18 , 1127 \u2013 1151 . 35287553",
    "full_text_abstract": "Abstract Neurodegenerative diseases encompass a spectrum of conditions characterized by the gradual deterioration of neurons in the central and peripheral nervous system. While their origins are multifaceted, emerging data underscore the pivotal role of impaired mitochondrial functions and endolysosomal homeostasis to the onset and progression of pathology. This article explores whether mitochondrial dysfunctions act as causal factors or are intricately linked to the decline in endolysosomal function. As research delves deeper into the genetics of neurodegenerative diseases, an increasing number of risk loci and genes associated with the regulation of endolysosomal and autophagy functions are being identified, arguing for a downstream impact on mitochondrial health. Our hypothesis centers on the notion that disturbances in endolysosomal processes may propagate to other organelles, including mitochondria, through disrupted inter\u2010organellar communication. We discuss these views in the context of major neurodegenerative diseases including Alzheimer's and Parkinson's diseases, and their relevance to potential therapeutic avenues.\n\nEndolysosomal and mitochondrial dysfunctions are major pathological hallmarks in neurodegeneration. In healthy neurons, lysosomes maintain mitochondrial health through membrane contact sites and local translation. In disease, failing lysosomal degradation compromises mitophagy, activating cGAS\u2010STING leading to further congestion and immune responses. Many risk genes in neurodegeneration indeed function in lysosomal/autophagy regulation."
}